Mutant prion proteins and uses thereof

Mutant prion proteins with threonine insertions in the TTTT motif inhibit prion misfolding and propagation, addressing the limitations of current TSE therapies by delaying disease progression without disrupting normal prion functions.

WO2026238920A1PCT designated stage Publication Date: 2026-11-19ASSOC CENT DE INVESTIGACION COOP & NANOCIENCIAS CIC NANOGUNE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/064143
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for transmissible spongiform encephalopathies (TSE) are inadequate, and reducing endogenous prion protein (PrP^c) levels to inhibit misfolding risks myelin maintenance, necessitating new tools to prevent PrP^c to PrP^Sc conversion.

Method used

Development of mutant prion proteins with specific amino acid modifications, such as a threonine insertion in the TTTT motif, to inhibit misfolding and prion propagation, using nucleic acids, expression vectors, and pharmaceutical compositions to deliver these proteins.

Benefits of technology

The mutant prion proteins effectively inhibit prion propagation and delay or prevent disease onset without affecting normal prion functions, demonstrating strain-independent and species-independent prion conversion blockade.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026064143_19112026_PF_FP_ABST
    Figure EP2026064143_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of mutant prion proteins that prevent prion proteins of misfolding into amyloid-like proteins, and their uses in medicine.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MUTANT PRION PROTEINS AND USES THEREOF

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to the field of mutant prion proteins that prevent prion proteins of misfolding into amyloid-like proteins, and their uses in medicine.

[0004] BACKGROUND OF THE INVENTION

[0005] Transmissible spongiform encephalopathies (TSE) or prion diseases are a group of rapidly progressing and invariably fatal neurodegenerative disorders affecting humans among other mammals and for which no treatment is available. In human beings, the best-known prion diseases include Creutzfeldt-Jakob diseases (CJD), fatal familial insomnia (FFI) and Gerstmann-Straussler-Scheinker syndrome (GSS), whereas in other mammals, scrapie from sheep and goat, bovine spongiform encephalopathy from cattle, and chronic wasting disease from deer are the most common.

[0006] Among the main hallmarks of these diseases are the spongiform changes in the brain, intense vacuolation due to extensive neuronal death, and the presence of amyloid plaques or deposits, large proteic aggregates that accumulate in the central nervous system. Being the latter a common characteristic of amyloidogenic or protein misfolding-related neurodegenerative diseases. In the case of TSE, these protein deposits are composed almost exclusively by an aberrantly folded (misfolded) isoform of the endogenous prion protein also known as cellular prion protein or PrPc. PrPcphysiological role, which is not exactly understood, appears to be related to the maintenance of myelin. Upon a poorly known misfolding event, the PrPccan undergo a structural change and acquire an alternative conformation named PrPSc(from scrapie) or prion. This aberrant isoform presents a high p-sheet content, becoming proteaseresistant and aggregation prone, forming amyloid fibrils with the capacity to induce the same conformation on natively folded PrPc, and thus, propagating and spreading through a self-templating polymerization process. Apart from protease resistance and self-propagating capacity, PrPScis also neurotoxic, its accumulation leading to neurodegeneration. Taking into account the proteic nature of prions and their propagation mechanism, TSE can arise from three different origins: 1) in the acquired or infectious forms of disease, PrPScis acquired from exogenous sources via ingestion of prion-contaminated biological tissues or fluids or via medical procedures with prion contaminated materials. This exogenous PrPScthen initiates its propagation process at the expense of the PrPcfrom the new host, invading the central nervous system and causing neurodegeneration. 2) In the familial or genetic TSE, mutations in the geneencoding PrPcresult in an enhanced misfolding capacity, eventually leading to PrPScformation that initiates the propagation process, presenting this kind of TSE an autosomal dominant inheritance. 3) Finally, in the idiopathic or sporadic forms of TSE, supposedly a rare event of wild-type PrPcmisfolding occurs, in the absence of pathology-associated mutations, leading again to PrPScformation and posterior propagation. Two remarkable phenomena have been reported in TSE, the existence of a transmission barrier and the existence of different prion strains. The latter are defined as different PrPScconformers that can show strikingly different biochemical and biological properties and thus, cause different disease types. The transmission barrier refers to when a PrPScfrom one species or polymorphic variant is acquired by a new host with the same PrPcspecies or variant, it propagates without any barrier in the new host, easily inducing its conformation and thus, strain features to the PrPcfrom the host. However, when the PrPcfrom the new host is different from the acquired PrPScstrain or variant, it can find difficulties to propagate at the expense of this PrPc. If completely unable to propagate there is a strong transmission barrier between PrPScand PrPc, the latter being unable to adopt the same conformation. Nonetheless, these barriers can be more easily overcome in other cases, sometimes keeping strain features despite an initial delay in disease progression, and other times through the emergence of a new strain in the host likely through imperfect templating. Hence, the capacity of a determined prion strain to induce its conformation or an alternative misfolding at the expense of a different PrPcsequence defines the host range of the strain.

[0007] Given the particular propagation mechanism of prions, the presence of natively folded or cellular PrP isoform, able to adopt a prion conformation, is essential as a conversion substrate for prion multiplication and spreading, and thus for the development of the neurodegenerative pathology.

[0008] In addition, the physical nature of prion misfolding and propagation process allows its replication in vitro, even in cell-free systems, in which the addition of minute amounts of PrPSc(seed) induce the conversion of the PrPcpresent in the reaction substrate, further proving that PrPc-PrPScinteraction is required for prion pathogenesis.

[0009] The invariably fatal nature of prion diseases as well as their transmissibility and zoonotic potential, able to cause epidemics such as that caused by transmission of bovine spongiform encephalopathy causing prions to humans resulting in the new variant Creutzfeldt-Jakob disease, has heightened the urgency to develop therapies for the TSE. Since the disease is driven by PrPcto PrPScconversion and thus, requires PrPcavailable for misfolding, reducing PrPcexpression levels either through anti-senseoligonucleotides or other regulators of protein expression, is one of the pursued strategies to cure or slow progression of TSE. Nonetheless, the reduction of an endogenous protein likely involved in myelin maintenance, is not without risks, as evidenced by subtle disease phenotypes recently found in animal models with reduction of PrPc, upon aging.

[0010] Therefore, new tools to inhibit or abolish the conversion of PrPcto PrPScare required.

[0011] SUMMARY OF THE INVENTION

[0012] The inventors have developed a method to evaluate the misfolding capacity of hundreds of natural recombinant prion protein (PrP) variants found in mammals in vitro, in a high throughput manner. With this method, the inventors detected dominant negative PrP candidates, that is, PrP variants / mutants that are unable to misfold neither spontaneously nor seeded with pre-formed prions and that are able to hinder the conversion of misfolding-susceptible PrP variants when mixed. These potentially dominant negative variants were further tested to assess their dominant negative or prion propagation inhibitory capacity, since if expressed in sufficient amounts in the brains of affected individuals they could hinder prion propagation and in consequence delay or even completely impede disease onset or progression, without the potential deleterious effects of reducing PrPclevels. Further analysis of these PrP candidates revealed an amino-acid signature that allowed prion proteins to be converted into mutant prion proteins unable to be misfolded into the amyloid-like, disease-associated form of the prion protein.

[0013] Therefore, a first aspect of the present invention relates to a mutant prion protein, wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type sequence is replaced by the sequence:

[0014] (S / V / T)(Z)mTT(X)n

[0015] wherein

[0016] Z is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, K, L, M, Q, R, S, T, V, Wand Y

[0017] m is an integer number between 1 and 3,

[0018] X is an amino acid selected from the group consisting of

[0019] A, F, H, I, K, L, M, R, S, T, V, W and Y

[0020] n is an integer number between 1 and 30,

[0021] >

[0022] and wherein if the wild-type protein has the TTTTT motif, thenif Z is T and X is T, then n is not 1 ,

[0023] if Z is T and n is 1 , then X is not T

[0024] if X is T and n is 1 , then Z is not T.

[0025] Another aspect of the present invention relates to a nucleic acid encoding the mutant prion protein according to the invention.

[0026] A further aspect relates to an expression vector comprising the nucleic acid according to the invention.

[0027] A further aspect relates to a host cell vector comprising the nucleic acid according to the invention or the vector according to the invention.

[0028] Yet another aspect relates to a pharmaceutical composition comprising the mutant prion protein according to the invention, the nucleic acid according to the invention, the vector according to the invention, or the host cell according to the invention, together with at least one pharmaceutically acceptable excipient.

[0029] One more aspect relates to the mutant prion protein according to the invention, the nucleic acid according to the invention, the expression vector according to the invention, the host cell according to the invention or the pharmaceutical composition according to the invention for use in medicine.

[0030] Another aspect relates to the mutant prion protein according to the invention, the nucleic acid according to the invention, the expression vector according to the invention, the host cell according to the invention or the pharmaceutical composition according to the invention for use in the treatment and / or prevention of a prion disease.

[0031] DESCRIPTION OF THE FIGURES

[0032] Figure 1. Alignment of bank vole, human, mouse, mule deer, sheep and 15 different cetacean recombinant PrP sequences with their corresponding misfolding scores. The spontaneous misfolding capacity of the recombinant versions of all prion proteins shown in the alignment was evaluated, resulting in the calculation of their misfolding proneness score, listed in the right of each rec-PrP sequence. Highlighted in black and in a white font is a threonine insertion only present in cetaceans that could be responsible for their resistance to misfolding.

[0033] Figure 2. Alignment of bank vole, human, mouse, mule deer, sheep, and their respective potentially dominant negative mutants including an extra cetaceanequivalent threonine with their comparative misfolding proneness score.

[0034] Potentially dominant negative rec-PrP were designed for several distinct species adding a fifth threonine in the TTTT string (InsT), mimicking that found in cetacean to assesswhether it impairs misfolding capacity irrespective of the recombinant protein used. The misfolding score assessed for these mutants, of 0 in all cases indicates that this threonine insertion could confer dominant negative capacity to any prion protein irrespective of the rest of the PrP sequence.

[0035] Figure 3. The effect of amino acid variations (substitutions and insertions) around the threonine string on the misfolding capacity of the bank vole recombinant PrP. A, bank vole PrP sequences with threonine insertions, together with their misfolding scores illustrate that the protective effect of the extra threonine is maintained when more than one T is added (at least up to 30 extra T). B, The protective effect associated with threonine is also observed when other amino acids are added to the sequence, as the ones shown in the alignment, with misfolding scores below 20. Whereas the insertion of other residues did not significantly impact the misfolding proneness, resulting in misfolding scores above 20. C, the effect of substituting amino acids in different positions in the threonine string was evaluated, showing that the number and the position of threonines seems to be critical, as the presence of more than two serines in different positions has a much less pronounced effect on misfolding. D, the relevance of the second position within the group of four threonines of the string to hinder misfolding was concluded from the previous mutants tested through the substitution by all existing amino acids which when substituted by each of the existing amino acids reveal that not all substitutions have the same effect on the protein's spontaneous misfolding. ND / NT: Non-tested.

[0036] Fig. 4. Evaluation of the effect of the deletion of the last threonine within the threonine string in cetaceans. The misfolding proneness of the four rec-PrP variants shown in the alignment was evaluated, showing that when the last threonine in the string is deleted in a recombinant dolphin PrP environment, this protein becomes susceptible to misfolding.

[0037] Fig. 5. Assessment of the ability of potentially dominant negative proteins to inhibit prion propagation and to interfere with prion propagation in permissive substrates. A, Murine rec-PrP with the threonine insertion (DN rec-PrP) and its wild type counterpart (wt rec-PrP) as positive control for prion propagation were used, each seeded with a recombinant murine prion previously obtained (btMi-09). Prion propagation was evaluated in duplicates (A and B) after two serial PMSA rounds (p01 and p02), showing rec-PrPres only in those tubes containing wild type rec-PrP and thus confirming that the threonine insertion effectively impedes seeded prion propagation. B, mixes of the same two proteins at 50 % were used to assess potential strain specificinhibitory effects. These, together with control substrates containing 100 % of either wt or DN rec-PrP, were seeded with 7 distinct recombinant mouse prions in duplicates (A and B). In all cases complete inhibition of prion propagation at 50:50 proportion of the DN and wt rec-PrP was observed, clearly indicating that threonine insertion results in a dominant negative protein, able to block propagation of susceptible substrates in a strain independent manner. C, To further define the efficacy of the inhibitory effect of the DN rec-PrP on interfering with the misfolding of the wt counterpart, mixes at proportions 100:0, 80:20, 75:25, 70:30 and 0:100 (wt rec-PrP:DN rec-PrP) were seeded in duplicates (A and B, except control substrates with 100 % of each rec-PrP) with the stMi-09 murine recombinant prion strain. As shown in the gel, rec-PrPres was undetectable even with the lowest amount of DN rec-PrP in the substrate (20 %). D, bank vole rec-PrP with the threonine insertion (DN rec-PrP) was mixed with its wild type counterpart (wt rec-PrP) at different proportions, to check if the results from mouse are applicable to other species. Upon seeding with a recombinant prion strain from bank vole (Ust02) the minimum percentage of DN rec-PrP necessary to inhibit completely the misfolding of the wt counterpart was determined, requiring 60%. To further explore interference capacity and strain specificity of the insertion conferring DN capacity in a bank vole PrP context, both proteins at 50:50 proportion were seeded with 6 different recombinant bank vole prion strains (Sst01 , Ust01 , Ust02, Ust05, Ust06 and Ust09). As shown in the gel, dependence of the inhibitory capacity for different strains was observed, wt: wild-type. DN: Dominant negative. MW: Molecular weight marker.

[0038] Fig. 6. Evaluation of the dominant negative capacity of other modified (deleted) proteins unable to misfold spontaneously. Dominant negative capacity of full-length bank vole rec-PrP with threonine insertion at position 194 (194lnsT vole), bank vole rec-PrP with a deletion of the first 90 amino acids (D90 vole) and bank vole rec-PrP with the same deletion but also with the threonine insertion (D90194lnsT vole), all unable to misfold spontaneously, was evaluated when mixed with full-length wild type bank vole rec-PrP (wt) at 50:50 proportion in duplicates (A and B) and seeded with a recombinant bank vole prion strain (Ust02). There was no prion propagation when using the dominant negative 194lnsT wild-type bank vole PrP at 100% or when the wild-type protein was mixed in a 50:50 ratio with the protein that, in addition to the threonine insertion, had a deletion of the first 90 amino acids. Nonetheless, the protein that had the same deletion but did not have the insertion showed no negative dominance. Undigested substrates were also included on the left side of the gel to demonstrate similar amounts of rec-PrPin the prepared substrates, wt: wild-type bank vole rec-PrP. DN: Dominant negative. MW: Molecular weight marker.

[0039] Fig. 7. Evaluation of the dominant negative capacity of other proteins unable to misfold spontaneously or induced by exogenous prions. Chicken rec-PrP, and two chimeric rec-PrP (vole-platypus and vole-bat chimeras), previously known unable to misfold spontaneously or propagate any known prion strain, mixed at 50:50 proportions with wild type bank vole rec-PrP (wt) were used in duplicates (A and B) and seeded with a bank vole recombinant prion (Sst01) to determine their potential dominant negative capacity in comparison to bank vole rec-PrP with the extra threonine insertion (194lnsT vole). Chicken PrP and the vole-platypus and vole-bat chimeric proteins, when at 100 % in the substrate, there is no rec-PrPres, demonstrating their incapability of misfolding and propagating pre-formed prions. However, when mixed at 50:50 with wt bank vole prion protein, rec-PrPres was formed in all cases proving their inability to interfere with the misfolding of bank vole PrP and thus, demonstrating they are not dominant negative proteins. Undigested substrates were also included at the left of the gel to show similar rec-PrP amounts in the substrates prepared, wt: wild-type bank vole rec-PrP. DN: Dominant negative. MW: Molecular weight marker.

[0040] Fig. 8. Biochemical analysis of the levels of expression of a dominant negative PrPcin the brains of mice following intravenous administration of L42 PrP DN AAV (9P31). Expression levels and anatomical distribution of a mouse PrP with the threonine insertion and the L42 epitope (L42 PrP DN) after intravenous AAV (9P31) administration in mice was evaluated by Western blotting. Notably, extensive expression of L42 PrP DN was observed in all brain areas. MW: Molecular weight marker.

[0041] Figure 9. Cetacean brain homogenates are refractory to prion propagation by brain-PMCA across multiple prion strains. Brain homogenates from five representative cetacean species spanning multiple families — bottlenose dolphin (Tursiops truncatus), long-beaked common dolphin (Delphinus capensis), fin whale (Balaenoptera physalus), Risso's dolphin (Grampus griseus), and striped dolphin (Stenella coeruleoalba) — were used as PMCA substrates and challenged with a diverse panel of prion seeds from different species and disease phenotypes: mouse-adapted scrapie strain RML, bovine spongiform encephalopathy (BSE), classical scrapie strain SSBP / 1 from sheep, and chronic wasting disease (CWD) from cervids. PMCA reactions were performed in quadruplicate for each substrate-seed combination through six serial rounds (R6 shown) of 48-hour amplification with 1:10 dilutions between rounds. Heat maps represent the percentage of positive replicates (out of 4) showing detectable PrPresby Western blot analysis, with the intensity gradient ranging from white (0% positive) to black (100% positive). Transgenic bank vole brain homogenate [TgVole(l109)1x] served as positive control for RML propagation, while TgBo110 transgenic cattle brain homogenate served as positive control for BSE and Tg338 and roe deer brain homogenates for SSBP / 1, and CWD strains, respectively. N / A indicates substrate-seed combinations not tested due to known incompatibility or redundancy. All cetacean substrates failed to support prion propagation (0% positive replicates) regardless of the prion seed used, demonstrating universal resistance across phylogenetically diverse prion strains. In contrast, control substrates showed robust PrPresaccumulation (100% positive replicates) with their respective compatible prion seeds, confirming the validity of the experimental conditions and the exceptional nature of cetacean resistance to prion propagation.

[0042] Figure 10. Extra threonine insertion completely prevents templated prion propagation across multiple species and strains. Seeded PMSA experiments were performed using recombinant PrP substrates from six mammalian species — bank vole, mouse, mule deer, elk, sheep, and human — each challenged with homologous prion seeds to eliminate species barrier effects. For each species, two distinct prion strains were tested: bank vole prion strains Ust02 and Ust09; mouse strains btML90 and stMLOl; chronic wasting disease strains De-174C and De-174D from mule deer; chronic wasting disease strains EI-399B and EI-399C from elk; scrapie strain ShVRQ9 from sheep (VRQ genotype) and strain ShARQI from sheep (ARQ genotype); and human strains EGM-1-3 and EGM-0-2. Prion seeds were serially diluted from 10'3to 10'8and used to seed PMSA reactions containing either wild-type recombinant PrP [PrP(wt)] or recombinant PrP with a threonine insertion immediately after the conserved tetrathreonine motif [PrP(+T)]. After 24-hour PMSA reactions, samples were analyzed for protease-resistant PrP by proteinase K digestion, electrophoresis, and total protein staining. Heat map indicates presence (light grey) or absence (dark grey) of detectable rec-PrPres. Wild-type substrates efficiently propagated all prion strains even at extreme dilutions (10-6to 10'8), demonstrating the sensitivity of the PMSA system. In striking contrast, all threonine insertion variants [PrP(+T)] failed to support prion propagation at any seed concentration, including the highest tested (10-3), across all twelve strainspecies combinations. This universal blockade demonstrates that the threonine insertion represents a modification capable of preventing templated prion conversion regardless of strain conformation or host species background.Figure 11. Single threonine insertion preserves strain-specific biochemical and neuropathological properties during prion propagation. Brain tissues from TgMo(L108l lns192T)1x mice terminally ill following intracerebral inoculation with RML, 22L, or ME7 prion strains were analyzed for biochemical and neuropathological characteristics and compared to tissues from TgMo(L108l)1x control mice inoculated with the same strains. A; Biochemical characterization of PrPresby Western blot analysis. Brain homogenates (10% w / v) from three representative animals per group were digested with proteinase K (80 pg / ml) and analyzed by Western blot using Sha31 antibody. Original inocula for each strain (RML, 22L, ME7) are shown in the leftmost lanes. All animals from both TgMo(L108l)1x and TgMo(L108l lns192T)1x groups displayed the characteristic three-band pattern of protease-resistant PrP (PrPres) corresponding to diglycosylated, monoglycosylated, and unglycosylated forms. Critically, glycoform ratios and electrophoretic mobility patterns were indistinguishable between TgMo(L108l)1x and TgMo(L108l lns192T)1x mice for each respective strain, demonstrating that the threonine insertion does not alter the fundamental biochemical properties of propagating prions despite significantly extending incubation periods. C57BL / 6 brain homogenate without proteinase K digestion serves as positive control for total PrP detection. MW, molecular weight markers. B; Neuropathological lesion profiles and immunohistochemical deposition patterns. Semi-quantitative assessment of spongiform vacuolation (upper plots, solid lines) and PrPresimmunoreactivity (lower graphs, dashed lines) across 14 neuroanatomical regions for RML-infected (top), 22L-infected (middle) and ME7-infected (down) animals, including intracerebral (leftside) and intraperitoneal (right side) inoculations, except for ME7 for which intraperitoneal inoculation is ongoing. Each point represents the mean severity score (scale 0-4) for the indicated brain region: piriform cortex (Pfc), hippocampus (H), occipital cortex (Oc), temporal cortex (Tc), parietal cortex (Pc), frontal cortex (Fc), striatum (S), thalamus (T), hypothalamus (HT), mesencephalon (M), medulla oblongata (Mob), cerebellar nuclei (Cm), cerebellar vermis (Cv), and cerebellar cortex (Cc). Additionally, micrographs from the parietal cortex (RML intracerebral, RML intraperitoneal, 22L intrcerebral and ME7 intraperitoneal) or the occipital cortex (22L intraperitoneal) from representative animals from each group are shown for hematoxylin & eosin staining (H&E, top images) and PrPresimmunostaining (IHC, lower images) (mAb 2G11, dil. 1:100). The three prion strains (RML, 22L and ME7) propagating in TgMo(L108l lns192T)1x mice, maintained strain-specific neuroanatomical targeting patterns characteristic of each strain, with RML showing predominant cortical involvement, 22L displaying characteristic cerebellarpathology and ME7 characterized by both cortical and cerebellar involvement and the presence of plaque-like aggregates. However, notable differences in lesion intensity were observed: RML-infected TgMo(L108l lns192T)1x mice showed reduced spongiform vacuolation in neocortex, mesencephalon, medulla oblongata, and cerebellar cortex, while displaying more intense PrPresimmunolabeling particularly in forebrain regions. This phenomenon was also observed in intraperitoneally inoculated animals, with notably higher PrPresimmunostaining intensity in all regions, although in terms of spongiosis, it was milder only in brainstem, with more marked lesions than the controls mainly in cortical regions. Similarly, 22L-infected TgMo(L108l lns192T)1x mice exhibited diminished spongiform lesion severity in neocortex, hippocampus, and piriform cortex, with relatively enhanced PrPresstaining in hypothalamus and mesencephalon. In this case, despite a similar trend could be appreciated in the intraperitoneally inoculated animals, errors during sampling and artifacts during preparation of fixed samples resulted in several areas being infra-represented in the lesion profiling, such as Pc, H, and HT in the control group and cerebellum in the TgMo(L108l lns192T)1x mice. Intracerebrally ME7-infected TgMo(L108l lns192T)1x mice showed similar spongiosis profile to TgMo(L1081)1 x mice but with higher scores in the hypothalamus and mesencephalon. Similarly higher immunostaining score were observed in these two regions in the TgMo(L108l lns192T)1x group but, conversely, with lower PrPresscores in the medulla oblongata and cerebellar structures. The intraperitoneally ME7 inoculated group is still ongoing at the moment of writing.. These altered intensity profiles while preserving strainspecific distribution patterns indicate that the threonine insertion modulates propagation efficiency without fundamentally altering the conformational properties or neuroanatomical tropism of prion strains.

[0043] Figure 12. Biochemical adaptation of RML prions to the double threonine insertion barrier is reversible upon return to a wild-type PrP environment. A.

[0044] Western blot analysis of brain homogenates following proteinase K digestion (80 pg / ml) and immunoblotting with Sha31 antibody. Left panel: Brain homogenates from C57BL / 6 control mice inoculated with parental RML (leftmost lanes) and from three representative TgMo(L108l lns192TT)1x mice that developed terminal prion disease following intraperitoneal inoculation with RML (lanes 1-3). RML prions that propagated in the double-insertion background displayed altered PrPresprofiles compared to parental RML, including a shift toward increased diglycosylation and a change in the electrophoretic mobility of the unglycosylated band. Right panel: Brain homogenates from C57BL / 6 mice subsequently inoculated with RML(+TT) prions (lanes 1-3), alongside C57BL / 6 controlsinoculated with parental RML. The PrPresprofile of RML(+TT) reverted to a pattern indistinguishable from that of the parental strain upon passage into the wild-type PrP environment, demonstrating that the biochemical alterations observed in TgMo(L108l lns192TT)1x mice represent transient conformational accommodations rather than heritable strain transformation. MW, molecular weight markers (kDa). B; Neuropathological lesion profiles and immunohistochemical deposition patterns from intraperitoneally RML-inoculated TgMo(L108l lns192TT)1x mice. Semi-quantitative assessment of spongiform vacuolation (upper plots, solid lines) and PrPresimmunoreactivity (lower graphs, dashed lines) across 14 neuroanatomical regions compared to intraperitoneally RML-inoculated TgMo(L108l)1x mice. Each point represents the mean severity score (scale 0-4) for the indicated brain region: piriform cortex (Pfc), hippocampus (H), occipital cortex (Oc), temporal cortex (Tc), parietal cortex (Pc), frontal cortex (Fc), striatum (S), thalamus (T), hypothalamus (HT), mesencephalon (M), medulla oblongata (Mob), cerebellar nuclei (Cm), cerebellar vermis (Cv), and cerebellar cortex (Cc). Additionally, micrographs from the parietal cortex from a representative animal from each group are shown for hematoxylin & eosin staining (H&E, top images) and PrPresimmunostaining (IHC, lower images) (mAb 2G11, dil. 1:100). Intraperitoneal RML infection of TgMo(L108l lns192TT)1x mice resulted in a synaptic PrPresdeposition pattern typical of the RML strain, with neocortical involvement. Nonetheless, lesion burden and immunostaining intensity were lower across the neocortex, hippocampus, pyriform cortex, and brainstem than in TgMo(L108l)1x mice. Despite marked inter-individual variability, including two animals with milder phenotypes characterized by predominant brainstem involvement and limited neocortical pathology, the findings indicate that the pathobiological features of the strain are largely preserved in this genotype.

[0045] Figure 13. Serial passage experiments demonstrate reversibility of biochemical adaptations upon return to wild-type PrP environment. Western blot analysis of brain homogenates from C57BL / 6 mice intracerebrally inoculated with prions that had been serially passaged through transgenic mice expressing PrP with threonine insertions. Brain tissues were collected from three representative animals per group at terminal disease and analyzed for PrPresfollowing proteinase K digestion (80 pg / ml) and immunoblotting with Sha31 antibody. Left panel: RML(+T) and 22L(+T) prions — RML and 22L strains that had propagated through primary passage inTgMo(L108l lns192T)1x mice — were inoculated into wild-type C57BL / 6 mice. The electrophoretic mobility patterns and glycoform ratios of PrPresin these animals were indistinguishable from thoseof the original parental RML and 22L strains, demonstrating that prolonged propagation in the presence of a single threonine insertion does not induce permanent conformational changes. The incubation periods in C57BL / 6 mice were similarly comparable to those of parental strains (see Table 3), confirming that the single additional threonine creates a kinetic barrier without fundamentally altering strain identity. Right panel: RML(+TT) prions — RML strain that had propagated through primary passage in TgMo(L108l lns192TT)1x mice and displayed biochemical alterations including altered glycoform ratios during propagation in the double-addition environment (Supplementary Figure 6A) — were inoculated into wild-type C57BL / 6 mice. Remarkably, the PrPrespattern reverted to that of the original parental RML strain, with indistinguishable electrophoretic mobility and glycoform ratios. This reversion to parental biochemical properties upon removal of the selective pressure demonstrates that the alterations observed during propagation in TgMo(L108l lns192TT)1x mice represent transient conformational accommodations rather than permanent strain transformation. The ability of prions to adopt alternative biochemical signatures under selective pressure, yet revert to the original conformation when that pressure is removed, reveals remarkable conformational plasticity without heritable strain conversion. Original RML and 22L inocula are shown in the leftmost lanes for direct comparison. C57BL / 6 brain homogenate without proteinase K digestion serves as positive control for total PrP detection. MW, molecular weight markers. B) Neuropathological lesion profiles and immunohistochemical deposition patterns from intracerebrally RML-inoculated C57BL / 6 mice (WT), TgMo(L108l lns192T)1x-passaged RML [RML(+T)] and TgMo(L108l lns192TT)1x-passaged RML [RML(+TT)] inoculated also in WT, and intracerebrally 22L-inoculated WT mice compared to TgMo(L108l lns192T)1x-passaged 22L [22L(+T)]. Semi-quantitative assessment of spongiform vacuolation (solid lines) and PrPresimmunoreactivity (dashed lines) across 14 neuroanatomical regions were analyzed for each group. Each point represents the mean severity score (scale 0-4) for the indicated brain region: piriform cortex (Pfc), hippocampus (H), occipital cortex (Oc), temporal cortex (Tc), parietal cortex (Pc), frontal cortex (Fc), striatum (S), thalamus (T), hypothalamus (HT), mesencephalon (M), medulla oblongata (Mob), cerebellar nuclei (Cm), cerebellar vermis (Cv), and cerebellar cortex (Cc). Additionally, micrographs from the parietal cortex from a representative animal from each group are shown for hematoxylin & eosin staining (H&E, top images) and PrPresimmunostaining (IHC, lower images) (mAb 2G11, dil. 1:100). Back-passage of RML after adaptation to the extra-threonine and double extra-threonine models into WT mice resulted in a synaptic PrPresdeposition pattern typical of the RMLstrain, with neocortical involvement, comparable to that of the original inoculum in WT mice. In the case of 22L, the histopathological features were also maintained upon inoculation of the extra-threonine adapted strain into WT, although lesion burden and immunostaining intensity were lower across most analyzed region. These findings indicate that the pathobiological features of both strains are largely preserved despite adaptation to the extra-threonine models in agreement with the biochemical properties.

[0046] Figure 14. Structural integrity of the T192_T193lnstTTT prion protein variant assessed by NMR spectroscopy. (A) Superposition of the NMR ensemble of human PrP T192_T193lnstTTT (residues 91-231; PDB 9TVY) with the wild-type PrP structure (PDB 1QLZ, grey). The three a-helices (a1-a3) and the antiparallel p-sheet are preserved, indicating that the overall fold of the protein remains intact upon threonine insertion. Flexible N-terminal residues are omitted for clarity. (B) Close-up view of the insertion region surrounding residue 194. The backbone trace of T192_T193lnstTTT overlays closely with the wild-type structure, and the inserted threonines (shown as sticks) do not introduce steric clashes or perturb the helical geometry. (C) CSP analysis comparing T192_T193lnstTT with wild-type PrP (BMRB 4402), calculated as Ab = > / [(Ab_H)2+ (0.2 Ab_N)2] for backbone amide resonances. CSPs are plotted for residues 91-232. Secondary structure elements derived from TALOS-N are shown in the background. Perturbations are predominantly localized near the insertion site, while the remainder of the structured domain shows minimal changes. The inset on the plot shows the CSP values mapped onto the NMR structure of T192_T193lnstTTT using B-factor representation, with color coding from low (light grey) to high (dark grey) perturbation. Perturbations cluster locally around the insertion region without affecting the global fold.

[0047] Figure 15. Three-dimensional visualization of fibril RMSF profiles confirms localized effects at the C-terminal lobe. Top view (along fibril growth axis) of complete prion fibril core structures from 1 ps molecular dynamics simulations, displayed in cartoon representation with color and thickness scaled according to per-residue Co RMSF values. Color coding indicates flexibility: lighter shading represents rigid regions with low RMSF (0.3 A), while darker shading indicates flexible regions with high RMSF (up to 1.5 A). Each fibril model comprises 12 stacked monomers arranged along the vertical axis (into the page). The C-terminal lobe tip containing the tetrathreonine motif and insertion site is highlighted within the grey dashed box on the right side of each structure. A; 22L strain fibril models. Three configurations are shown: top, wild-type (WT) fibril composed entirely of unmodified mouse PrP monomers, showing relatively uniform light coloring throughout most of the structure with higher flexibility (red) at the C-terminallobe tip; middle, lns192T fibril (p.T192_T193insT) composed entirely of monomers carrying the threonine insertion, displaying reduced flexibility at the C-terminal lobe tip (light grey) compared to WT; bottom, mixed WT / lns192T fibril containing alternating wildtype and lns192T monomers in 1:1 ratio, with the two chains at the WT / lns192T interface labeled. This mixed model exhibits appreciably elevated flexibility specifically at the C-terminal lobe (dark) in the K194-M206 stretch, while the core p-sheet region maintains lower flexibility (lighter coloring), demonstrating that the structural perturbation induced by the sequence mismatch is localized to the insertion site region and does not propagate throughout the fibril architecture. B; RML strain fibril models, displayed in the same format as panel A. Top, RML WT fibril showing lower flexibility at the C-terminal lobe (darker coloring) compared to 22L WT; middle, RML lns192T fibril exhibiting increased flexibility at the C-terminal lobe tip (darker coloring) relative to WT — the opposite trend observed in 22L; bottom, RML mixed WT / lns192T fibril showing elevated flexibility at the C-terminal lobe, specifically in the Q186-E200 region. This differential response between strains might correlate with the observed strain-specific protective efficacy in vivo, where 22L showed greater susceptibility to threonine insertion-mediated inhibition (103-109% incubation period extension) compared to RML (32-36% extension). The localized nature of the structural perturbations — confined primarily to the C-terminal lobe despite the presence of the insertion — supports the conclusion that the protective mechanism operates through specific disruption of templated conversion in different regions in the proximity of the insertion site rather than through global destabilization of amyloid structure.

[0048] Figure 16. Inter-rung distance distributions reveal strain-dependent disruption of -sheet packing in mixed fibrils. Histograms of Ca-Ca distances between consecutive rungs (inter-rung separation) measured across 1 ps molecular dynamics trajectories for prion fibril models. Inter-rung distance is a critical structural parameter reflecting the tightness of p-sheet packing in amyloid fibrils: shorter distances indicate compact, well-ordered stacking, while longer distances reflect looser packing and structural perturbations. The ideal inter-rung separation of 4.882 A (corresponding to the p-strand spacing in parallel p-sheets) is indicated by a dashed vertical line, representing the reference distance from cryo-EM structures. Histogram bins within ±1 A of this reference value (4-6 A range) are dark grey, representing the normal distribution expected for stable amyloid fibrils. Bins corresponding to longer distances (>6 A) are light grey and indicate regions of looser p-sheet packing. Frequency indicates the number of distance measurements falling within each bin throughout the simulation. A;22L strain fibril models. Three histograms show distributions for: left, wild-type (WT) fibril displaying a tight distribution centered near the reference distance (~4.9 A), with minimal population in violet bins, indicating stable, well-packed p-sheets; center, lns192T fibril (p.T192_T193insT) showing a similar tight distribution centered near the reference, demonstrating that homogeneous fibrils containing only lns192T monomers maintain normal p-sheet packing and do not destabilize the overall fibril architecture; right, mixed WT / lns192T fibril showing a markedly different distribution with substantial population shift toward longer distances (light grey bins, highlighted by an arrow), reflecting looser P-sheet packing at the WT / lns192T interface due to the sequence mismatch. This shift toward longer inter-rung distances indicates structural incompatibility between wild-type and lns192T monomers, creating a significant barrier to fibril elongation when the two variants must co-assemble. B; RML strain fibril models, displayed in the same format as panel A and referenced to the RML cryo-EM structure (PDB ID: 7QIG). Left and center panels show that both RML WT and lns192T fibrils maintain tight distributions centered near the reference distance. Right, the RML mixed WT / lns192T fibril also exhibits population shift toward longer distances (dark grey bins), but this shift is noticeably less pronounced than in the corresponding 22L mixed model, indicating that RML tolerates the structural mismatch better than 22L. This differential response correlates directly with in vivo observations: 22L showed greater susceptibility to threonine insertion-mediated protection (103-109% incubation period extension) compared to RML (32-36% extension). These inter-rung distance distributions complement the RMSF analyses (Fig.

[0049] 15) by revealing that the protective mechanism operates through disruption of p-sheet packing specifically at interfaces between wild-type and insertion-containing monomers. The preservation of normal packing in homogeneous lns192T fibrils explains why RML prions eventually propagated in single-insertion mice: once adapted, they can form stable fibrils composed entirely of modified PrP. In contrast, the substantial packing disruption in mixed fibrils creates a kinetic barrier to fibril elongation during the adaptation phase, accounting for the prolonged incubation periods observed in vivo.

[0050] DETAILED DESCRIPTION OF THE INVENTION

[0051] The inventors have developed a method to evaluate the misfolding capacity of hundreds of natural recombinant prion protein (PrP) variants found in mammals in vitro, in a high throughput manner. With this method, they detected dominant negative PrP candidates, that is, PrP variants / mutants that are unable to misfold neither spontaneously nor seeded with pre-formed prions and that are able to hinder theconversion of misfolding-susceptible PrP variants when mixed. Further analysis of these PrP candidates revealed an amino-acid signature that allowed to prion proteins to be converted into mutant prion proteins unable to misfold into the amyloid-like, disease-associated form of the prion protein.

[0052] Mutant prion proteins of the invention

[0053] Therefore, a first aspect of the present invention relates to a mutant prion protein, from here onwards the mutant prion protein of the invention, wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type sequence is replaced by the sequence:

[0054] (S / V / T)(Z)mTT(X)n

[0055] wherein

[0056] Z is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, L, K, M, Q, R, S, T, V, Wand Y

[0057] m is an integer number between 1 and 3,

[0058] X is an amino acid selected from the group consisting of

[0059] A, F, H, I, K, L, M, R, S, T, V, W and Y

[0060] n is an integer number between 1 and 30,

[0061] and wherein if the wild-type protein has the TTTTT motif, then

[0062] if Z is T and X is T, then n is not 1 ,

[0063] if Z is T and n is 1 , then X is not T

[0064] if X is T and n is 1 , then Z is not T.

[0065] Alternatively, the first aspect of the present invention relates to a mutant prion protein wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wildtype sequence is replaced by the sequence:

[0066] TZTT(X)n

[0067] wherein

[0068] Z is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, L, K, M, Q, R, S, T, V, Wand Y,

[0069] X is an amino acid selected from the group consisting of

[0070] A, F, H, I, K, L, M, R, S, T, V, W and Y

[0071] n is an integer number between 1 and 30,

[0072] and wherein if the wild-type protein has the TTTTT motif, then

[0073] if Z is T and X is T, then n is not 1 ,

[0074] if Z is T and n is 1 , then X is not T

[0075] if X is T and n is 1 , then Z is not T.As used herein, the term “wild-type” refers to proteins occurring in nature or not artificially generated, such as by genetic engineering. In the present invention, the wildtype prion protein is a protein comprising an amino-acid sequence which naturally occurs in nature. In a preferred embodiment the wild-type prion protein is a prion protein naturally occurring with a protein sequence comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with a selected from a group consisting of: NCBI Protein database accession number NP_001073592.1, entry version 1 of February 3, 2026, NCBI Protein database accession number AAH 12844.1, entry version 1 of September 23, 2014, NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025, NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, and NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026.

[0076] In a preferred embodiment the wild-type prion protein is a prion protein naturally occurring with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity, preferably at least 85%, 90% or 95% identity across the whole length of the protein sequence of the protein according to the protein sequence with the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026 or with the accession number AAH12844.1 of the NCBI Protein database, entry version 1 of September 23, 2014.

[0077] In a preferred embodiment the wild-type prion protein is a prion protein naturally occurring with a protein sequence consisting of the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026 or of the accession number AAH 12844.1 of the NCBI Protein database, entry version 1 of September 23, 2014.

[0078] As used herein the term "mutant" refers to a protein disclosed in the present invention, in which one or more amino acids with respect to the wild-type protein are added and / or substituted and / or inserted at the N-terminus, and / or the C-terminus,and / or within the native amino acid sequences of the proteins of the present invention. As used herein the term "mutant" also refers to a nucleic acid molecule that encodes a mutant protein. Moreover, the term "mutant" refers to any shorter or longer version of the protein or nucleic acid herein. In the present context the mutant protein refers to the mutant prion protein. In a particular embodiment, the mutant prion protein is a protein that does not exist in nature and has an amino acid sequence that differs from the sequence of a naturally existing prion protein. In another particular embodiment, the mutant prion protein is synthetically obtained.

[0079] In a particular embodiment, the mutant prion protein is a protein that does not exist in nature and comprises less than 100% sequence identity, preferably less than 99.5%, 99%, 98.5%, 98%, 97.5%, 97%, 96.5%, 96%, 95.5%, 95%, 94.5%, 94%, 93.5%, 93%, 92.5%, 92%, 91.5%, 91%, 90.5%, 90%, 89.5%, 89%, 88.5%, 88%, 87.5%, 87%, 86.5%, 86%, 85.5%, 85% or less sequence identity, and at least 50% or more sequence identity with the corresponding wild type sequence, wherein the sequence identity is calculated across the whole length of the mutant prion protein, preferably wherein the corresponding wild type sequence is selected from a group consisting of: NCBI Protein database accession number NP_001073592.1, entry version 1 of February 3, 2026, NCBI Protein database accession number AAH 12844.1, entry version 1 of September 23, 2014, NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025, NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, NCBI Protein database accession number AAB70468.1 , entry version 1 of September 1997, and NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026.

[0080] In a particular embodiment, the mutant prion protein is a protein that does not exist in nature and comprises a sequence which has a difference in identity of between 0.1% and 50%, preferably a difference in sequence identity of 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 45% or 50% with the corresponding wild type sequence, wherein the difference in sequence identity is calculated across the whole length of the mutant prion protein, more preferably wherein the corresponding wild type sequence is selected from a group consisting of: NCBIProtein database accession number NP_001073592.1, entry version 1 of February 3, 2026, NCBI Protein database accession number AAH 12844.1, entry version 1 of September 23, 2014, NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025, NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, and NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026.

[0081] In a particular embodiment, the mutant prion protein is a protein that does not exist in nature wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wildtype sequence is replaced by the sequence:

[0082] TZTT(X)n

[0083] wherein

[0084] Z is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, L, K, M, Q, R, S, T, V, Wand Y,

[0085] X is an amino acid selected from the group consisting of

[0086] A, F, H, I, K, L, M, R, S, T, V, W and Y

[0087] n is an integer number between 1 and 30,

[0088] >

[0089] and wherein if the wild-type protein has the TTTTT motif, then

[0090] if Z is T and X is T, then n is not 1 ,

[0091] if Z is T and n is 1 , then X is not T

[0092] if X is T and n is 1 , then Z is not T.

[0093] In another particular embodiment, the mutant prion protein is a protein that does not exist in nature and comprises:

[0094] a protein sequence according to the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026, wherein the amino acids at positions 190-193, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0095] a protein sequence according to the accession number AAH 12844.1 of the NCBI Protein database, entry version 1 of September 23, 2014, wherein theamino acids at positions 190-193, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0096] a protein sequence according to the accession number NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025, wherein the amino acids at positions 190-193, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0097] a protein sequence according to the accession number NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, wherein the amino acids at positions 189-192, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0098] a protein sequence according to the accession number NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO:134-143.;

[0099] a protein sequence according to the accession number NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0100] a protein sequence according to the accession number NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0101] a protein sequence according to the accession number NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, wherein the amino acids at positions 194-197, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0102] a protein sequence according to the accession number NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, wherein theamino acids at positions 209-302, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;

[0103] a protein sequence according to the accession number NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143; and

[0104] a protein sequence according to the accession number NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026, wherein the amino acids at positions 189-192, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143.

[0105] The term “prion”, “prion protein”, “PrP”, “cellular PrP”, are used interchangeably and as used herein refers to a protein which has two states of conformation, one not “disease-associated form”, also known as cellular form, or PrPc, wherein the protein has the potential to change into the “disease-associated form of the prion protein”, also known as “PrP scrapie” or “PrPSc”, and when in the PrPScform it has the capacity to induce the misfolding of PrPcproteins into PrPSc. Prions are therefore, a transmissible particle known to cause a group of such transmissible conformational diseases (such as spongiform encephalopathies) in humans and animals. "Prions" are distinct from bacteria, viruses and viroids. Known prions include those that infect animals to cause scrapie, a transmissible, degenerative disease of the nervous system of sheep and goats as well as bovine spongiform encephalopathies (BSE) or mad cow disease and feline spongiform encephalopathies of cats. Four prion diseases known to affect humans are Kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Strassler-Scheinker Disease (GSS), and fatal familial insomnia (FFI). As used herein prion includes all forms of prions causing all or any of these diseases or others in any animals and in particular in humans and in domestic farm animals.

[0106] The standard method to determine if a protein is a prion is by analysis of tissue with amyloid deposits or fibers, and analysis of said amyloid deposits in order to determine the protein composition of said amyloid deposit. Other computational methods also exist, which through protein sequence analysis determine the probability of a protein to be a prion. Examples of such computational methods are the pWaltz Model (Sabate,R et al. PLoS Comput Biol. 2015 Jan; 11(1): e1004013) and the PAPA Model (Toombs JA. et al., Proc Natl Acad Sci U S A 2012, 109: 6519-6524).

[0107] One of the hallmarks of the prion protein associated diseases is the presence of amyloid proteins, also called amyloid deposits, which are composed by misfolded prion protein. The term “amyloid protein” as used herein refers to a protein capable of forming an amyloid deposit or a fragment thereof. The terms “amyloid deposit”, “amyloid aggregate”, “amyloid fibril” and “amyloid plaque” refer to a protein deposit which causes a disease, formed from misfolding of the protein that changes the random coil or a-helical structure of a secondary or tertiary structure into a p-sheet, and an “prion protein monomer” refers to the protein before the conformational change occurs.

[0108] In the context of the present invention, the mutant prior proteins are prion proteins that have been mutated in order to reduce or abolish its capacity to adopt a misfolded conformation, and therefore not being capable of being converted into the amyloid-like, disease-associated form of the prion protein. In a particular embodiment of the invention, the mutant prion protein has a reduced or abolished capacity of misfolding into amyloid-like conformation. In another particular embodiment of the invention, the mutant prion protein is not capable of being converted into the amyloid-like, disease-associated form of the prion protein.

[0109] The capacity of misfolding can be determined by determining the misfolding score (S) as exemplified in the examples of the present specification. In a particular embodiment the reduction in the misfolding capacity is of at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% in the misfolding score when compared to the wild-type prion protein. In another particular embodiment of the invention, the mutant prior protein has a misfolding score of 20% or less, preferably less than 20%, less than 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, more preferably of 0%.

[0110] Another method to determine if a prion protein has misfolded into an amyloid-like, disease-associated form of the prion protein is by determining if the prion protein is resistant to proteinase digestion. In a particular embodiment of the invention, the mutant prion protein is susceptible to proteinase degradation. In another particular embodimentof the invention, the mutant prion protein is susceptible to proteinase degradation, wherein the proteinase is proteinase K.

[0111] Without wanting to be bound to any particular theory, it is considered that some prion proteins that are unable to misfold might be dominant negatives. The inability to misfold would not be the only requirement of a prion protein to be a dominant negative, but it is considered a necessary requirement. It is considered that a mutant prion protein is unable to misfold spontaneously when the mutant prion protein has a misfolding score of 20% or less. Hence, in a particular embodiment, the mutant prion protein of the invention has a misfolding score of 20% or less. In a more particular embodiment the mutant prion protein has a misfolding score of less than 20%, less than 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or 0%.

[0112] The term “dominant negative PrP” or “DN PrP” as used herein refers to a mutant PrP which, not only is unable to misfold spontaneously, but also it is able to hinder or block the propagation of a prion, likely because it is unable to adopt the conformation of the specific prion strain, and either by competition or simple physical blocking, can interfere with the propagation of the susceptible substrate. Therefore, in a particular embodiment of the present invention, the mutant prion protein has an inhibitory effect on the conversion of an endogenous wild-type prion protein that is naturally present in an organism. The term “inhibitory effect” as used herein refers to the capacity of the mutant prion protein to reduce the probability of a wild type prion protein to misfold into the amyloid-like conformation. As previously mentioned, the probability of a wild type prion protein to misfold into an amyloid-like conformation can be determined by the misfolding score. Therefore, in a particular embodiment, the inhibitory effect of the mutant prior protein on the conversion of an endogenous wild-type prion protein that is naturally present in an organism is a reduction of at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% of the misfolding score (S) of the endogenous wild-type prion protein.

[0113] The mutant prion proteins of the invention are characterized in that the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type sequence is replaced by the sequence (S / V / T)(Z)mTT(X)n.Alternatively, the mutant prion proteins of the invention are characterized in that the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type sequence is replaced by the sequence TZTT(X)n. The term “motif” as used herein refers to an amino acid sequence, irrespective of its configuration, capable of being part of a natural, mutant or synthetic protein or peptide, designated by its single-character code such as, e.g., represented in the table 1 below.

[0114] Table 1 : Codes of the amino acids

[0115] Single letter code Amino Acid

[0116] A alanine

[0117] C cysteine

[0118] D aspartic acid

[0119] E glutamic acid

[0120] F phenylalanine

[0121] G glycine

[0122] H histidine

[0123] I isoleucine

[0124] K lysine

[0125] L leucine

[0126] M methionine

[0127] N asparagine

[0128] P proline

[0129] Q glutamine

[0130] R arginine

[0131] S serine

[0132] T threonine

[0133] V valine

[0134] W tryptophan

[0135] Y tyrosine

[0136]

[0137] The term “motif” as used herein is also meant to include a nucleotide capable of being part of a synthetic nucleic acid or oligonucleotide sequence designated below by its single-character code: A, G, C, T or II, corresponding to the nomenclature of the respective base (adenine A, guanine G, cytosine C or thymine T in the DNA, or uracil II in the RNA) of which they are constituted.The term “sequence” is understood to mean any chaining of motifs as defined above capable of constituting a sequence of a nucleic acid or a fragment thereof of a living organism or a sequence of a protein or a fragment thereof of a living organism, including wild type sequences, mutant sequences or artificial sequences similar to those obtained by chemical or biological synthesis according to methods known in the art. As non-limitative examples, it is understood that a sequence containing such motifs can be a group of genes, a gene or a fragment thereof, a group of proteins, a protein or a fragment thereof.

[0138] Naturally occurring prion proteins are characterized by the presence of a threonine string, which is a motive of four or five threonines. In the context of the present inventions, said threonine motifs are modified, in particular, the motifs TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2), are replaced by the sequence (S / V / T)(Z)mTT(X)n, wherein Z is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, K, L, M, Q, R, S, T, V, Wand Y,

[0139] m is an integer number between 1 and 3,

[0140] X is an amino acid selected from the group consisting of

[0141] A, F, H, I, K, L, M, R, S, T, V, W and Y

[0142] n is an integer number between 1 and 30,

[0143] and wherein if the wild-type protein has the TTTTT motif, then

[0144] if Z is T and X is T, then n is not 1 ,

[0145] if Z is T and n is 1 , then X is not T

[0146] if X is T and n is 1 , then Z is not T.

[0147] In a particular embodiment of the invention, Z is an amino acid selected from the group consisting of P, E, D, H, I, F, K, L, M, R, S, T, V, W and Y.

[0148] The symbol “(Z)m” is meant to represent that the amino acid “Z” is repeated sequentially in the motif sequence “n” times, wherein n is an integer number between 1 and 3. In a particular embodiment of the invention n is 1 , 2, or 3.

[0149] In another particular embodiment of the invention X, is an amino acid selected from the group consisting of T, S and V.

[0150] The symbol “(X)n” is meant to represent that the amino acid “X” is repeated sequentially in the motif sequence “n” times, wherein n is an integer number between 1 and 30. In a particular embodiment of the invention n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.

[0151] The mutant protein of the invention has at least one modification in the threonine motif with respect to the sequence of the wild type prion protein. Therefore, if the wildtype prion protein has a TTTT motif, that is a string with just four threonines, the modification can be the insertion of at least one additional “X” residue at the end of the motif, and / or the replacement of the second threonine by an amino acid selected from the group consisting of F, L, M, Q, R, S, V, W and Y.

[0152] However, if the wild type prion protein has a TTTTT motif, that is, a string with five threonines, at least the second and / or the fifth threonine has to be replaced by other amino acid, or at least an additional residue has to be included at the end of the motif. Therefore, if the wild-type protein has the TTTTT motif, then

[0153] - if Z is T and X is T (meaning that none of the second or fifth threonine is replaced), then n is not 1 (meaning that at least one additional residue should be included at the end of the motif),

[0154] - if Z is T and n is 1 (meaning that the second threonine of the motif is not replaced and no additional residue is included at the end of the motif), then X is not T (meaning that the fifth threonine is modified),

[0155] - if X is T and n is 1 (meaning that the fifth threonine of the motif is not replaced and that no additional residue is included at the end of the motif), then Z is not T (meaning that the second threonine is replaced by other amino acid).

[0156] In a particular embodiment of the invention, the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type protein is replaced by a sequence selected from the group consisting of:

[0157] TTTT(T)n, wherein n is an integer number between 1 and 30 (SEQ ID NO: 2, SEQ ID NO: 114-132, 134-143),

[0158] TTTTX (SEQ ID NO: 9), wherein X is selected from the group consisting of A, K, S, V, F, L, I, M, Y, H, W, R,

[0159] - TTTT(S)n, wherein n is 2 or 3 (SEQ ID NO: 10 and SEQ ID NO: 11),

[0160] - TTTT(V)n, wherein n is 2 or 3 (SEQ ID NO: 12 and SEQ ID NO: 13),

[0161] - SSTTT (SEQ ID NO: 4),

[0162] - TAAATT (SEQ ID NO: 5),

[0163] - TAAATTT (SEQ ID NO: 6),

[0164] - TATTT (SEQ ID NO: 7),

[0165] TZTTT (SEQ ID NO: 8), wherein Z is selected from the group consisting of: A, K, R, S, Y, P, F, E, G, D, H, L, I, M, Q and W.

[0166] In a particular embodiment of the invention, the mutant prion protein of the invention further comprises a deletion of three amino acids which flank the C-terminusof the motif TTTT (SEQ ID NO: 1) or the motif TTTTT (SEQ ID NO: 2) which is replaced according to the invention.

[0167] In a particular embodiment of the invention, the mutant prion protein of the invention further comprises a deletion of one or two amino acids at both the C-terminal and the N-terminal end of the motif TTTT (SEQ ID NO: 1) or the motif TTTTT (SEQ ID NO: 2) which is replaced according to the invention.

[0168] In a particular embodiment of the invention, the mutant prion protein of the invention further comprises the deletion of the first asparagine residue located immediately beyond the C-terminus of the motif TTTT (SEQ ID NO: 1) or the motif TTTTT (SEQ ID NO: 2) which is also replaced according to the invention.

[0169] In a further embodiment of the invention, the mutant prion protein of the invention derives from the wild-type prion protein according to the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026, wherein the motif TTTT (SEQ ID NO: 1) is replaced according to the invention, and the mutant prion protein further comprising:

[0170] the deletion of asparagine residue located at position 196 at the C-terminus of the motif TTTT (SEQ ID NO: 1);

[0171] the deletion of amino acids at positions 189, and 194, which flank both ends of the motif TTTT (SEQ ID NO: 1);

[0172] the deletion of amino acids at positions 188, 189, 194, 195, which flank both ends of the motif TTTT (SEQ ID NO: 1); or

[0173] the deletion of amino acids at positions 188, 189, 194, 195, 196, which flank both ends of the motif TTTT (SEQ ID NO: 1).

[0174] In a particular embodiment, the mutant prior protein comprises a sequence selected from the group consisting of SEQ ID NO: 15-30, 23-36, 39-40, 42-54, 59-61, 64-88 and 109-113.

[0175] Nucleic Acids, vectors and host cells

[0176] The mutant prion proteins of the invention can be encoded by nucleic acids, which can be present in vectors and / or in host cells.

[0177] As such, another aspect of the present invention relates to a nucleic acid encoding the mutant prion protein of the invention, from here onwards the nucleic acid of the invention.

[0178] The terms “nucleic acid” and “polynucleotide”, as used herein interchangeably, refer to a polymer composed of nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants and synthetic non-naturally occurringanalogs thereof or combinations thereof) linked via phosphodiester bonds, related naturally occurring structural variants and synthetic non-naturally occurring analogs thereof.

[0179] The person skilled in the art will acknowledge that the nucleic acid encodes the polypeptide or protein sequence of the mutant prion protein of the invention that corresponds to the first aspect of the invention. The nucleic acid of the invention therefore comprises the sequence encoding the mutant prion protein, including the modified motifs.

[0180] The nucleic acid of the invention encoding the mutant prion protein of the invention can be part of a vector. Thus, in another aspect, the invention relates to an expression vector comprising the nucleic acid of the invention, from here onwards the vector of the invention. The term “vector”, as used herein, refers to a construct capable of delivering, and optionally expressing, one or more polynucleotides of interest into a host cell. A person skilled in the art will understand that there is no limitation as regards the type of vector which can be used because said vector can be a cloning vector suitable for propagation and for obtaining the polynucleotides or expression vectors in different heterologous organisms suitable for purifying the fusion proteins of the invention. The term “cloning vector”, as used herein, refers to a vector suitable for propagation and to obtain the adequate polynucleotides or gene constructs or expression vectors in different heterologous organisms suitable for the purification of the vector. The term “expression vector”, as used herein, refers to a vector suitable for expression of a polynucleotide in a target cell. Thus, suitable vectors according to the present invention include expression vectors in prokaryotes such as pET (such as pET14b), pUC18, pUC19, Bluescript and their derivatives, mp18, mp19, pBR322, pMB9, ColEI, pCRI, RP4, phages and shuttle vectors such as pSA3 and pAT28, expression vectors in yeasts such as vectors of the type of 2 micron plasmids, integration plasmids, YEP vectors, centromeric plasmids and the like, expression vectors in insect cells such as the pAC series and pVL series vectors, expression vectors in plants such as vectors of expression in plants such as pl Bl, pEarleyGate, pAVA, pCAMBIA, pGSA, pGWB, pMDC, pMY, pORE series vectors and the like and expression vectors in superior eukaryotic cells based on viral vectors (adenoviruses, viruses associated to adenoviruses as well as retroviruses and lentiviruses) as well as non-viral vectors such as pSilencer 4.1-CMV (Ambion), pcDNA3, pcDNA3.1 / hyg pHCMV / Zeo, pCR3.1, pEFI / His, pIND / GS, pRc / HCMV2, pSV40 / Zeo2, pTRACER-HCMV, pUB6A / 5-His, pVAXI, pZeoSV2, pCI, pSVL and pKSV-10, pBPV-1,pML2d and pTDTI. In a particular embodiment the vector of the invention is an adeno-associated viral vector (AAV).

[0181] The vector of the invention can be used to transform, transfect, or infect cells which can be transformed, transfected or infected by said vector. Said cells can be prokaryotic or eukaryotic. By way of example, the vector wherein said DNA sequence is introduced can be a plasmid or a vector which, when it is introduced in a host cell, is integrated in the genome of said cell and replicates together with the chromosome (or chromosomes) in which it has been integrated. Said vector can be obtained by conventional methods known by the persons skilled in the art (Sambrook et al., 2001, “Molecular cloning, to Laboratory Manual”, 2nd ed., Cold Spring Harbor Laboratory Press, N.Y. Vol 1-3 a). Therefore, another aspect of the invention also relates to a host cell comprising the nucleic acid of the invention or expression vector of the invention, from here onwards the host cell of the invention. The term “host cell”, as used herein, refers to a cell into which a nucleic acid of the invention, such as a polynucleotide or a vector according to the invention, has been introduced and is capable of expressing the polynucleotides of the invention. Said host cell has been able to be transformed, transfected or infected with a polynucleotide or vector provided by this invention. The transformed, transfected or infected cells can be obtained by conventional methods known by persons skilled in the art (Sambrook et al., 2001, mentioned above).

[0182] Host cells suitable for the expression of the conjugates of the invention include, without being limited to, mammal, plant, insect, fungal and bacterial cells. Bacterial cells include, without being limited to, Gram-positive bacterial cells such as species of the Bacillus, Streptomyces, Listeria and Staphylococcus genera and Gram-negative bacterial cells such as cells of the Escherichia, Salmonella and Pseudomonas genera. Fungal cells preferably include cells of yeasts such as Saccharomyces cereviseae, Pichia pastoris and Hansenula polymorpha. Insect cells include, without being limited to, Drosophila and Sf9 cells. Plant cells include, among others, cells of crop plants such as cereals, medicinal, ornamental or bulbous plants. Suitable mammal cells in the present invention include epithelial cell lines (human, ovine, porcine, etc.), osteosarcoma cell lines (human, etc.), neuroblastoma cell lines (human, etc.), epithelial carcinomas (human, etc.), glial cells (murine, etc.), hepatic cell lines (from monkey, etc.), CHO (Chinese Hamster Ovary) cells, COS cells, BHK cells, HeLa cells, 911, AT1080, A549, 293 or PER.C6, NTERA-2 human ECC cells, D3 cells of the mESC line, human embryonic stem cells such as HS293, BGV01, SHEF1, SHEF2, HS181, NIH3T3 cells, 293T, REH and MCF-7 and hMSC cells.In a preferred embodiment of the invention, the nucleic acid, the vector, and the host cell of the invention are suitable for the expression of the mutant prion protein of the invention.

[0183] Pharmaceutical compositions and medical uses

[0184] The mutant prion protein of the invention or a pharmaceutical composition comprising it finds uses in the treatment of prion associated diseases.

[0185] Hence, an aspect of the present invention relates to a pharmaceutical composition, from here onwards the pharmaceutical composition of the invention, comprising the mutant prion protein of the invention, the nucleic acid of the invention, the expression vector of the invention, or the host cell of the invention, together with at least one pharmaceutically acceptable excipient.

[0186] As used herein, the term "pharmaceutically acceptable excipient" means a nontoxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Remington's Pharmaceutical Sciences. Ed. by Gennaro, Mack Publishing, Easton, Pa., 1995 discloses various expedients used in formulating pharmaceutical compositions and known techniques for the preparation thereof.

[0187] The pharmaceutical compositions of this invention can be administered to a patient by any means known in the art including oral and parenteral routes. According to such embodiments, inventive compositions may be administered by injection (e.g., intravenous, subcutaneous, intramuscular, intraperitoneal, intrathecal, intracranial injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).

[0188] Another aspect of the present invention relates to the mutant prion protein of the invention, the nucleic acid of the invention, the expression vector of the invention, the host cell of the invention or the pharmaceutical composition of the invention for use in medicine. Alternatively, the invention relates to the use of the mutant prion protein of the invention, the nucleic acid of the invention, the expression vector of the invention, the host cell of the invention or the pharmaceutical composition of the invention in the manufacture of a medicament.

[0189] Another aspect of the present invention relates to the mutant prion protein of the invention, the nucleic acid of the invention, the expression vector of the invention, the host cell of the invention or the pharmaceutical composition of the invention for use in the treatment and / or prevention of a prion disease, from here onwards the medical use of the invention. Alternatively, the invention relates to the use of the mutant prion proteinof the invention, the nucleic acid of the invention, the expression vector of the invention, the host cell of the invention or the pharmaceutical composition of the invention for the manufacture of a medicament for the treatment and / or prevention of a prion disease. Alternatively, the invention relates to a method for the treatment / prevention of a prion disease comprising administering to a subject in need thereof the mutant prion protein of the invention, the nucleic acid of the invention, the expression vector of the invention, the host cell of the invention or the pharmaceutical composition of the invention.

[0190] As used herein, the terms "treat", "treatment" and "treating" refer to the reduction or amelioration of the progression, severity and / or duration of prion disease, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of prion disease. The terms "treat", "treatment" and "treating" also refer to the amelioration of at least one measurable physical parameter of prion disease, such as increase of amyloid deposits, not necessarily discernible by the patient. Furthermore, "treat", "treatment" and "treating" refer also to the inhibition of the progression of prion disease, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. "Treat", "treatment" and "treating" may refer, too, to the reduction or stabilization of amyloid deposits.

[0191] As used herein, the term "prion disease" refers to the group of prion-mediated degenerative disorders known as spongiform encephalopathies. In humans, these diseases comprise different types of Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI) and Kuru, among others. Prion diseases occurring in other mammals comprise scrapie in sheep and goats, and bovine spongiform encephalopathy (BSE) in cattle, as well as prion diseases in other ruminants and cats. In a particular embodiment of medical use of the invention, the prion disease is selected from the group consisting of Creutzfeldt-Jakob diseases (CJD), fatal familial insomnia (FFI), Gerstmann-Straussler-Scheinker syndrome (GSS), scrapie, bovine spongiform encephalopathy, chronic wasting disease, Variably Protease-Sensitive Prionopathy (VPSPr) and Prion Protein Systemic Amyloidosis.

[0192] ***

[0193] The invention is described below by way of the following examples which are to be taken as merely illustrative and not limiting the scope of the invention.

[0194] EXAMPLES

[0195] Example 1

[0196] Materials and MethodsRecombinant prion protein expression and purification

[0197] Expression and purification of recombinant PrP (from amino acids 23 to 231 in bank vole PrP numbering, devoid of the N-ter signal peptide), either obtained from genomic DNA of the species through PCR or by synthesis, were cloned into pOPIN E expression vector, developed by Oxford Protein Production Facility UK (OPPF). After transforming them in E. coli Rosetta™ (DE3) competent cells (EMD Millipore), they were grown in ampicillin containing LB broth and recombinant protein expression induced using Isopropyl p-D-1 -thiogalactopyranoside (IPTG) (Gold biotechnology). Purification was done through immobilized metal affinity chromatography using His-trap columns (HisTrap FF crude 5 ml, GE Healthcare Amersham) taking advantage of the histidine-rich octapeptide repeat (OR). After solubilizing inclusion bodies containing most of the rec-PrP, the clarified cell extract was loaded into the column, washed, and eluted (in elution buffer, 20 mM Tris-HCI, 500 mM NaCI, 500 mM imidazole and 2 M guanidine-HCI, pH 8). After elution, guanidine-HCI concentration was increased up to 6 M for longterm storage at -80°C and then, protein concentration adjusted to 25 mg / ml using centrifugal filter units (Amicon® Ultra-15 PLGC Ultracel-PL 10 KDa, Millipore) and performing measurements of absorbance at 280 nm (Nanodrop). Finally, protein amount and purity were evaluated by total protein staining (BlueSafe, Nzytech) after methanol precipitation and electrophoresis in SDS-PAGE gels (BioRad).

[0198] Substrate preparation for Protein Misfolding Shaking Amplification

[0199] The purified rec-PrP stored at -80 °C was diluted 1:5 in phosphate buffered saline (PBS, Hyclone) and dialyzed for re-folding against PBS at 1:2,000 ratio for 1 h at room temperature. The dialyzed protein was centrifuged at 19,000 g for 15 min at 4 °C to eliminate amorphous aggregates and the supernatant was used for substrate preparation. The dialyzed proteins, with a concentration of around 20 pM given similar yields upon re-folding, were diluted in conversion buffer (CB, 0.15 M NaCI and 1 % Triton-X-100 in PBS) 1:9, and dextran sulfate sodium salt from Leuconostoc spp. with molecular weights ranging from 6,500 to 10,000 (Sigma-Aldrich) was added to a final concentration of 0.5 % (w / v). All substrates were aliquoted and stored at -80 °C until required.

[0200] Evaluation of spontaneous misfolding proneness of distinct recombinant PrP by PMSA

[0201] Protein Misfolding Shaking Amplification (PMSA) is a recently developed in vitro prion generation method, derived from the well-known Protein Misfolding Cyclic Amplification (PMCA), specifically adapted to obtaining recombinant bona fide prions in vitro.The method is based on a reaction substrate composed by recombinant PrP (rec-PrP) at 0.1 mg / ml, produced in E. coli and purified through immobilized metal affinity chromatography, complemented with 0.5 % (w / V) dextran sulphate as polyanionic cofactor, all diluted in conversion buffer. The PMSA substrates, containing distinct rec-PrP were placed in 2 ml screw-cap tubes together with 0.1 g of acid-washed 1 mm diameter glass beads or 0.01 g of acid washed 0.1 mm diameter glass spheres (BioSpec Products, Inc.), and submitted to 24 h PMSA reaction. The reactions were performed in a Thermomixer (Eppendorf) ora Digital shaking Drybath (ThermoScientific) with internal temperature control, set at 39 °C and with continuous shaking at 700 rpm. For each distinct rec-PrP, 4 duplicates with 1 mm beads and 4 with 0.1 mm beads were set and after 24 h reaction, detection of misfolded protease-resistant rec-PrP (rec-PrPres) or recombinant prions was done through proteinase K (PK) digestion of the PMSA products, electrophoresis and total protein staining. Four serial 24 h PMSA rounds were performed for each replicate, diluting 1:10 the PMSA product from the previous round in fresh substrate with the same amount and type of glass beads / spheres and submitting the new tubes to additional 24 h PMSA reaction in the same conditions. The number of tubes showing rec-PrPresin each round, monitored through PK digestion, electrophoresis and total protein staining, was then used to rank the misfolding proneness of each prion protein and detect those with lowest misfolding propensity or unable to acquire prion conformation. A numerical score was calculated for each rec-PrP taking into account the number of replicates positive for rec-PrPresin each round and with each bead type, assigning higher misfolding proneness to those showing rec-PrPresin more replicates and earlier in terms of PMSA round number. In addition, given that the smallest glass spheres pose greater difficulties than the large ones for rec-PrP misfolding through PMSA, replicates with the largest beads positive for rec-PrPreswere assigned higher scoring values in order to make the system more restrictive for the detection of rec-PrP with lowest possible misfolding proneness. Taking all this into account, the number of rec-PrPrespositive replicates in each serial PMSA round was multiplied for the following values as displayed in Table 2:

[0202] Table 2: PSMA rounds.

[0203] PMSA round 1 (R1) PMSA round 2 (R2) PMSA round 3 (R3) PMSA round 4 (R4) 0.1 mm 1 mm 0.1 mm 1 mm 0.1 mm 1 mm 0.1 mm 1 mm 4 10 2.4 6 1.2 3 0.4 1

[0204]

[0205] Thus, tubes positive for rec-PrPresin earliest rounds and with 1 mm glass beads were assigned the highest misfolding score in agreement with the following formula: M

[0206]

[0207] P = * 10 + 71R1-0.1 * 4) + (?1R2-1 * 6 + HR2-0.1 * 2.4) + (?1R3-1 * 3 + HR3-0.1 * 1.2)

[0208] + (71.R4-1 * 1 + 71R4-0.1 * 0.4)

[0209] Where MP is the misfolding proneness, r)Ri-i is the number of rec-PrPrespositive replicates in PMSA round 1 with 1 mm beads, DRI-O.I is the number of rec-PrPrespositive replicates in PMSA round 1 with 0.1 mm beads, nR2-i is the number of rec-PrPrespositive replicates in PMSA round 2 with 1 mm beads and nR2-o.i with 0.1 mm beads, and so on up to PMSA round 4. According to the formula, rec-PrP showing all replicates positive from the first PMSA round would present the maximum misfolding score, with a value of 112, whereas those unable to misfold would show a score of 0, being selected as potential dominant negative proteins. To facilitate interpretation of misfolding score ranking, the MP for each rec-PrP tested, derived from the previous formula, where normalized to 100 to present the misfolding score as percentage:

[0210]

[0211] Where S is the Misfolding Score in percentage and MP is the misfolding proneness calculated for each rec-PrP according to the previous formula.

[0212] Using the PMSA procedure described above and the scoring system shown, the misfolding score (S) of hundreds of different rec-PrP was evaluated, selecting those with an S of 0 % as potential dominant negative (DN) proteins given their incapacity to misfold spontaneously. The ability to inhibit prion propagation for those proteins selected here was further evaluated through prion propagation assays and competition or interference assays by PMSA.

[0213] Evaluation of prion propagation inhibitory capacity of distinct recombinant PrP by PMSA

[0214] The inability to misfold spontaneously in PMSA was the first selection criteria for potentially DN prion proteins. However, for a PrP to act as a real dominant negative, it requires to inhibit also prion propagation when in contact with pre-formed prions (inhibit the self-propagation capacity of infectious prions). Most importantly, it needs to exert the same effect when mixed with PrP susceptible to misfolding, such as that homologous to the prion used to seed the PMSA reaction. To assess if the potential DN proteins selected for their inability to misfold spontaneously, were also unable to misfolding induced by pre-formed prions, they were submitted to a seeded PMSA reaction, using previously generated and characterized recombinant prions as seeds.PMSA, as well as for spontaneous prion misfolding, can be applied with minimum adaptations to prion propagation, where minute amounts of pre-formed recombinant prions can be propagated or multiplied at the expense of the rec-PrP from the substrate through structural templating and nucleation-polymerization of prion fibrils. Instead of using glass beads or spheres, which promote spontaneous rec-PrP misfolding, the same amounts of zirconia-silica beads of 1 mm diameter (Sigma-Aldrich) can be mixed with the substrate to achieve propagation while avoiding spontaneous misfolding.

[0215] Therefore, to test whether the proteins unable to misfold spontaneously were also unable to acquire prion conformation when induced with pre-formed prions, PMSA substrates containing the selected rec-PrP complemented with sulphated dextran were placed in 2 ml screw-cap tubes with 0.1 g of 1 mm zirconia-silica beads. Recombinant prions obtained from a previous PMSA reaction were then added as seed at 1:10 dilution (seed: substrate). Given that prion propagation can be limited by a transmission barrier partially depending on PrP sequence differences between seed and substrate, in all cases, the seeds with the closest PrP sequence were chosen for each substrate. As a proof of concept, mouse rec-PrP with a substitution potentially conferring dominant negative capacity and bank vole rec-PrP with the same substitution were tested, using their respective wild-type proteins as controls of misfolding susceptible rec-PrP. Additionally, taking into account that different prion strains can show differential propagation capacity at the expense of the same substrate, different recombinant strains were used as seeds for each substrate in order to avoid strain-specific effects on propagation capacity. As prion propagation is generally a more efficient process than spontaneous misfolding, a single or a maximum of two-rounds PMSA of 24 h were performed for each seed-substrate combination, with two replicates for each and using the same reaction conditions as for the spontaneous PMSA. Propagation capacity was determined through the detection of rec-PrPresin each tube after PMSA, using again PK digestion, electrophoresis and total protein staining.

[0216] Assessment of the ability of potentially dominant negative proteins to interfere with prion propagation in permissive substrates

[0217] Once demonstrated that rec-PrP unable to misfold spontaneously were also resistant to seeded prion propagation, we needed to assess their capacity to interfere with prion propagation in an environment where there is also a misfolding-susceptible PrP. As this feature necessary to consider that, a PrP presents dominant negative capacity impeding prion propagation, and thus disease progression, in an environmentcontaining also misfolding-susceptible or wild-type PrP being this the scenario in a real therapeutic setting.

[0218] To assess this interference capacity and thus, consider such PrP variant a DN protein, PMSA was used again. In this case, the reaction substrates contained different proportions of the potential DN rec-PrP and the corresponding wild-type rec-PrP, without any substitution conferring DN capacity. Substrates mixing both rec-PrP at 100:0, 30:70, 40:60, 50:50, and 0:100 proportions were prepared, all complemented with sulfated dextran and with zirconia-silica beads as in the previous seeded PMSA setting. As a proof of concept, mouse and bank vole rec-PrP with DN substitution and their respective wild-type proteins were used in duplicates, seeded in all cases 1:100 (seed:substrate) with pre-formed recombinant prions as in the previous assay. All the tubes were submitted to a round of 6-12 h PMSA and presence or absence of rec-PrPreschecked by PK digestion, electrophoresis and total protein staining. As positive controls, in order to compare rec-PrPressignal in mixed substrates with the expected signal from wild type proteins, substrates containing only wild-type proteins in the same amounts as in the mixed substrates were used, since prion propagation is limited by the amount of misfolding-susceptible rec-PrP in the substrate. As in the previous assay, multiple different recombinant prion strains were used as seeds for each substrate to rule out strain-specific interference or inhibition. Interference, indicating that the selected proteins show DN capacity, was determined by comparing rec-PrPressignals in mixed substrates with their respective controls containing the same amounts of only wild-type protein.

[0219] rec-PrPresdetection by electrophoresis and total protein staining

[0220] All PMSA products were transferred from the reaction tubes to 1.5 ml Eppendorf tubes and digested by adding proteinase K (PK) (Roche) at 25 pg / ml for 1 h at 42 °C in an oven (Nahita). Following digestion, samples were centrifuged at 19,000 g at 4 °C for 15 min, the supernatant discarded, and the pellets were resuspended and washed with at least 700 pl of PBS (Fisher Bioreagents). Then, samples were centrifuged for another 5 min at 19,000 g and 4 °C, and the pellets were resuspended in 15 pl of loading buffer 4x (NuPage LDS, Invitrogen), previously diluted to 1x in PBS. PK-resistant PrP detection was done through electrophoresis and total protein staining. PK-digested samples were boiled for 10 min at 100 °C and loaded onto 4-12 % acrylamide gels (NuPAGE Midi gel, Invitrogen Life Technologies). Electrophoresis was run for 1 h and 20 min (10 min at 70 V, 10 min at 110 V and 1 h at 150 V) and stained with BlueSafe (NZYTech) for 1 h at room temperature.Results

[0221] All recombinant PrP variants with an extra Threonine within the Thr string motif are unable to misfold spontaneously

[0222] The spontaneous misfolding proneness of all PrP variants from distinct mammals shown aligned in Figure 1 was evaluated by PMSA. Whereas known prion susceptible species such as bank vole, mouse, human, mule deer and sheep rec-PrP showed misfolding proneness scores ranging from 30 to 100 %, all cetacean proteins, belonging to dolphin, baiji, beluga whale, sperm whale, whale, ziphius, narrow-ridged finless porpoise, Pacific white-sided dolphin, South Asian river dolphin, Sowerby’s beaked whale, La Plata dolphin, Stejneger’s beaked whale and Northern bottlenose whale presented a score of 0. The reason for this inability of cetacean PrP to misfold could lie on a threonine insertion within the threonine string motif, as it is unique to these species unlike other amino acid variations that can be found also in misfolding susceptible PrP.

[0223] Insertion of the extra threonine from cetaceans in rec-PrP variants susceptible to misfolding demonstrates its role on inhibiting spontaneous prion misfolding

[0224] To confirm that the additional threonine found exclusively in cetaceans is the underlying cause of their resistance to adopt pathogenic prion conformation and not dependent on the interaction with any other motif from cetacean PrP, this residue was inserted in the equivalent position of rec-PrP variants previously shown highly susceptible to misfolding. Thus, bank vole (1109 polymorphic variant), human (M129 polymorphic variant), mouse, deer and sheep rec-PrP (ARQ polymorphic variant) with an extra Thr (named InsT) were produced and their misfolding proneness was evaluate by PMSA to compare them with their wild type, misfolding-susceptible counterparts. As shown in the right of the sequences in Figure 2, the misfolding scores of these potentially dominant negative variants was in all cases 0 %, in contrast to the scores of the wildtype versions with scores ranging from 30 to 100 %. That is, insertion of the extra Thr from cetaceans in rec-PrP with variable degrees of misfolding proneness completely abrogated their misfolding capacity, indicating this Thr insertion is sufficient to render diverse prion proteins unable to adopt the pathogenic prion conformation.

[0225] Diverse variations in the Threonine string motif show a dramatic impact in the misfolding capacity of one of the species most susceptible to misfolding To narrow down potential substitutions and insertions able to confer dominant negative capacity to a prion protein and shed light on the exact substitutions in this region of the protein that may also result in dominant negative PrP, several bank vole rec-PrPvariants were designed with substitutions and insertions described in the tables from Figure 3. All changes with respect to the wild type protein are described within the tables and flanking 5’ and 3’ sequences are also included. Panel A gathers all the variants designed to assess if additional Thr insertions in the same region exert the same effect as that observed with a single Thr insertion. Once again, misfolding proneness scores of all these variants, with up to 20 Thr insertions, were determined by PMSA, resulting in a misfolding score of 0 % in all cases and thus, demonstrating that from 1 to at least 20 Thr insertions within this motif lead to the same misfolding capacity inhibition. Then, whether the insertion of other amino acids within the Thr string could have a similar effect than the Thr insertion was assessed by the same PMSA methodology, using the rec-PrP variants shown in panel B. Several amino acids, inserted instead of the extra Thr, conferred the same misfolding incapacity. In particular, serine, valine, phenylalanine, leucine, isoleucine, methionine, tyrosine, histidine, lysine, tryptophan and arginine insertions withing the Thr string showed the same misfolding inhibitory effect as the extra Thr insertion, reducing misfolding score to 0 %. Along this line, the insertion of alanine and asparagine albeit showing a milder effect than the rest, significantly reduced spontaneous misfolding capacity, both variants showing misfolding scores below 40 %. However, not any amino acid insertion reproduced the effect, since proline, glutamine, asparagine, aspartic acid, glutamic acid, and glycine insertions resulted in misfolding scores above 50 %, with some being as prone to misfolding as the wild type bank vole PrP. Therefore, from these results, we can conclude that not any alteration in the threonine string leads to a potential dominant negative effect. As in the case of variants from panel A, multiple insertions of residues with a similar effect to the extra Thr, such as serine and valine, resulted in a complete inhibition of the misfolding capacity of the proteins, demonstrating that multiple insertions of determined residues exert the same effect as the single amino acid insertion. After proving that one or multiple insertions of specific amino acids in the threonine string motif can dramatically alter the misfolding capacity of the rec-PrP, we sought to determine if the rest of the threonine residues naturally present in the threonine string of all rec-PrP analysed are necessary for the inhibitory effect of the fifth threonine insertion. For that, a new set of bank vole rec-PrP variants with distinct substitutions within the string were designed that are described in panel C, based on two amino acids (alanine and serine) that previously showed some inhibitory effect when introduced mimicking the fifth threonine found in cetaceans. Overall, the results indicate that some of the threonine residues within the string are critical for the insertion of a fifth amino acid to block misfolding capacity of the PrP, andthus, that not any alteration of the threonine string leads to the generation of prion proteins with potential dominant negative capacity. According to the variants showing lowered or enhanced misfolding capacity, we conclude that the first, third and fourth threonine of the motif need to be conserved, in order for the insertion of a fifth residue at the end of the string to result in a significant reduction of misfolding ability. Whereas the second residue and the fifth extra amino acid, withstand certain variations without losing the protective effect initially observed for threonine. Finally, to further define the residues that could be placed instead of the second threonine while keeping the misfolding inhibitory effect, the rec-PrP variants listed in panel D were generated and submitted to the same PMSA assay to calculate their spontaneous misfolding scores. As indicated by the misfolding scores of these variants, substitution of the second threonine for serine, valine, proline, phenylalanine, glutamic acid, aspartic acid, histidine, leucine, isoleucine, methionine, arginine, lysine, tryptophan and tyrosine results in the same inhibitory effect than the original threonine. The substitution by alanine, glycine, asparagine and glutamine also led to some inhibition although with lower impact than the previous substitutions. Other variants included in this panel D, further demonstrate, the relevance of keeping the first, third and fourth threonine residues in the string, since their substitution by other residues, albeit impairing in most cases misfolding capacity, show much more modest effect than those variants maintaining these most critical residues.

[0226] Deletion of the fifth threonine from the threonine string in a cetacean recombinant PrP confirms its pivotal role on inhibiting spontaneous misfolding To further demonstrate that the presence of a fifth threonine within the threonine string is key for the resistance to spontaneous misfolding observed in cetaceans, recombinant dolphin PrP with the last threonine deleted was designed (Del194T). This protein was produced in E. coli, purified and used as substrate in PMSA to determine its spontaneous misfolding proneness score in comparison with its wild type counterpart, recombinant bank vole PrP and the bank vole rec-PrP with threonine insertion. As depicted in Figure 4, the misfolding score of the rec-PrP from the dolphin with the fifth threonine deleted was 87 %, indicating a high proneness to misfolding in striking contrast to the wild type counterpart that was unable to misfold. These results further demonstrate the effect of the fifth threonine as key on the misfolding resistance, irrespective of the environment of the rest of the protein, the effect being comparable to what happens in bank voles with a threonine insertion, and has previously been seen for other recombinant mammalian PrP sequences.Prion protein variants with the threonine insertion are resistant to prion propagation and able to impair it even in presence of misfolding-susceptible proteins

[0227] In addition of the incapacity to misfold spontaneously, a dominant negative prion protein needs to be also resistant to misfolding induced by pre-formed prions, called propagation, and able to interfere with this process even in the presence of PrP susceptible to it. Therefore, in order to assess first if the threonine insertion conferring resistance to spontaneous misfolding was also able to confer resistance to prion-induced misfolding, mouse recombinant PrP was used comparing the prion propagation capacity of a variant with threonine insertion (DN rec-PrP) with its wild type counterpart (wt rec-PrP). As shown in Figure 5A, two distinct PMSA substrates were prepared with equal amounts of either wild type or DN mouse rec-PrP that were afterwards seeded with minute amounts of a previously misfolded recombinant murine prion called stMi-09. Through two serial 24 h rounds of PMSA rounds their capacity to propagate the recombinant murine prion was evaluated, detecting proteinase K resistant PrP (rec-Prpres) indicative of prion propagation, only in the substrate containing the wild type rec-PrP, demonstrating the ability of the variant with an extra threonine to block prion propagation. Once determined that both spontaneous and prion-induced misfolding were avoided due to the threonine insertion, its capacity to interfere with or block prion propagation in substrates containing both, the dominant negative PrP and the wild type, misfolding-susceptible counterpart was evaluated. For that, murine rec-PrP with the threonine insertion (DN rec-PrP) and its wild type counterpart (wt rec-PrP) were mixed in at 100:0, 50:50 and 0:100 proportions (DN rec-PrP : wt rec-PrP) in the PMSA substrates. In addition, to check for potential strain-specific inhibitory effects, 7 different recombinant murine prion strains were used as seeds (stMi-01, stMi-03, stMi-05, stMi-09, stML-01, btML-89 and btML-90). The results shown in Figure 5B prove that 50 % of the DN rec-PrP was in all cases sufficient to inhibit completely prion propagation that occurs in absence of this variant. Furthermore, the result suggests that there is no strain specific inhibitory effect, given that the presence of 50 % of DN rec-PrP was sufficient to inhibit prion propagation for all the strains tested. To further assess the effectiveness of the murine dominant negative PrP, substrate mixes containing less than 50 % of the DN rec-PrP mixed with wt rec-PrP were prepared (100:0, 80:20, 75:25, 70:30, 0:100). In this case, substrates with the same amount of the wild type rec-PrP were also included (80:0, 75:0 and 70:0), as controls of propagation in reduced rec-PrP substrates, given that prion propagation efficiency is proportional to the amount of PrP in the substrate. For thispurpose, the distinct substrates containing mixes of DN rec-PrP and wt rec-PrP were seeded with the recombinant murine prion stMi-09 and submitted to a single 24 h PMSA round. After proteinase K digestion, electrophoresis and total protein staining for the detection of misfolded rec-PrP, results shown in Figure 5C demonstrate that even the lowest amount of DN rec-PrP analysed, 20 %, was able to inhibit prion propagation completely. Finally, to assess whether the dominant negative capacity conferred by the threonine insertion to murine rec-PrP was also applicable to other species, bank vole rec-PrP with the same insertion (DN rec-PrP) was used together with its wild type counterpart (wt rec-PrP) at different proportions (40:60 and 30:70, wt rec-PrP: DN rec-PrP). As observed previously with mouse rec-PrP, the presence of bank vole rec-PrP with the threonine insertion completely inhibited the propagation of the recombinant bank vole prion strain Ust02 at the different proportions tested, as can be seen in Figure 5D. However, when evaluating strain specificity of the inhibitory capacity in this species using 6 different bank vole prion strains (Sst01, Ust01, Ust02, Ust05, Ust06 and Ust09) as seeds for PMSA, a strain dependent inhibition was observed. Figure 5E shows that 50 % of DN rec-PrP from bank vole was sufficient to inhibit prion propagation completely when seeded with Ust01 and Ust02 strains, whereas for the other four strains only a moderate inhibition can be observed, as indicated by reduced signal intensity.

[0228] Dominant negative effect of the threonine insertion is independent of other large alterations in the prion protein sequence

[0229] T o demonstrate that a significant change (deletion) in a PrP variant with a threonine insertion does not alter its capacity for negative dominance, the ability of a variant showing a deletion of the first 90 amino acids of PrP (D90) was evaluated and tested alongside a control that contained the same deletion but did not have the threonine insertion in PrP. Forthat, we prepared different substrates, each containing 100% of a single PrP variant (100:0 or 0:100), 50% of a single PrP variant as a control for the expected prion propagation level (when there is no interference from the potential dominant negative (DN) protein), and 50:50 mixes of the various potential DN proteins with the corresponding wild-type protein, which in all cases was wild-type bank vole PrP. All substrates containing different PrP variants were seeded with a bead pre-loaded with recombinant bank vole prions (Sst01 strain). After a single PMSA round of 5 h for prion propagation all samples were digested with proteinase K and the presence of misfolded rec-PrP was assessed by electrophoresis and total protein staining. Results shown in Figure 6 confirm the inhibitory capacity of bank vole PrP with the extra threonine (1941 nsT vole) when mixed with its wild type counterpart at 50:50 proportions. On thecontrary, the protein with the deletion of the first 90 amino acids at the same proportion permitted the propagation of the full-length wild type rec-PrP despite being unable to propagate the Sst01 prions under the same conditions. Notably, the same D90 protein with the extra threonine completely blocked the propagation of the wild type when mixed at 50:50, demonstrating that its dominant negative capacity its conferred by the threonine insertion and not the deletion of the first 90 amino acids.

[0230] Not all prion protein variants unable to misfold spontaneously or propagate pre-formed prions show dominant negative capacity

[0231] To demonstrate that not any PrP variant unable to misfold spontaneously or induced by previously formed recombinant prions shows dominant negative capacity, the ability of 3 different misfolding-resistant PrP variants to interfere with the misfolding of a susceptible PrP was assessed. Two chimeric PrP variants with the N and C-terminal fragments from bank vole and central region of platypus and bat, and the PrP from chicken, all unable to misfold neither spontaneously nor seeded with recombinant prions, were evaluated in comparison with the bank vole PrP with the threonine insertion at position 194, already known to act as a dominant negative. For that, different substrates were prepared containing either 100 % of a single PrP variant, 50 % of a single PrP variant as control of the prion propagation level expected (when there is no interference from the potentially dominant negative (DN) protein), and 50:50 mixes of the distinct potential DN proteins with the corresponding wild-type protein, that was in all cases the wild type bank vole PrP. All of them were seeded with Sst01 recombinant bank vole prion strain and underwent a single 5 hour PMSA round, the results of which are depicted in Figure 7. As for previous experiments, bank vole rec-PrP with the extra threonine showed complete inhibition of prion propagation at amounts of 50 % in the substrate. In contrast, vole-bat and vole-platypus chimeric proteins, both unable to propagate Sst01 prions, allowed its propagation at 50:50 proportions with the wild type bank vole protein, as did the PrP from chicken. Thus, this study demonstrates that not all PrP variants unable to misfold or propagate prion misfolding can interfere with the misfolding of susceptible variants, other yet unknown characteristics being necessary for a PrP to exert a dominant negative effect.

[0232] Preliminary analysis of the expression levels of the dominant negative protein achieved in brains of mouse after intravenous AAV administration

[0233] To determine if the dominant negative prion proteins can be expressed at high levels in the brain using an adeno-associated viral vector (AAV 9P31) and intravenous administration, and asses the distribution of the dominant negative protein in differentbrain regions, a new mouse PrP variant was designed to be expressed through AAV. This protein contained the additional threonine insertion conferring dominant negative capacity and the epitope for the L42 anti-prion antibody that does not recognize the endogenous wild type version thanks to a single substitution. AAV of 9P31 serotype, able to cross the blood-brain barrier expressing this PrP variant were then produced and inoculated intravenously in mice that were euthanized 21 days after injection. Brains from these animals were then harvested and divided in different anatomical areas to analyze the dominant negative PrP expression levels by Western blot, using the L42 antibody. The results, shown in Figure 8, reveal very high levels of expression of the dominant negative proteins in all brain areas examined, indicating that it is feasible to achieve high expression levels of this protein, which could be enough to inhibit prion misfolding and propagation also in vivo.

[0234] Example 2

[0235] Materials & Methods

[0236] Ethics statement - Animal welfare approvals and regulatory compliance All animal experiments were conducted in strict accordance with European Union Directive 2010 / 63 / EU on Laboratory Animal Protection and Spanish national legislation regarding the protection of animals used for scientific purposes. All procedures received prior authorization from the corresponding institutional animal welfare ethics committees.

[0237] Transgenic mouse generation: The transgenic mouse lines TgMo(L108l)1x, TgMo(L108l T192_T193lnstT)1x, and TgMo(L108l T192_T193lnstTT)1x were generated at the Transgenic Facility of the Institute for Biomedical Research of Salamanca (IBSAL) and University of Salamanca, under ethical approval code JCyL-1084 from the Institutional Animal Welfare Ethics Committee.

[0238] Multi-institutional experimental procedures: Prion inoculation studies and bioassays were carried out across multiple Spanish research centers, including CIC bioGUNE (Derio), Neiker — Basque Institute for Agricultural Research and Development (Derio), and the Centre for Experimental Biomedicine (CEBEGA, University of Santiago de Compostela). Each institution obtained independent ethical approval through their respective animal welfare committees under the following authorization codes: CIC bioGUNE (P-CBG-CBBA-0314 and 15,005 / 16 / 006), Neiker (NEIKER-GEBA-2021-003), and CEBEGA (15012 / 2023 / 002).

[0239] Regulatory framework: All experimental procedures were performed in compliance with "Real Decreto 53 / 2013 de 1 de febrero" on the protection of animals used forexperimentation and other scientific purposes, which transposes European Directive 2010 / 63 / EU on Laboratory Animal Protection into Spanish national law.

[0240] Generation of recombinant PrP expression constructs

[0241] All recombinant prion protein variants analyzed in this study were generated using the pOPIN E expression vector (Oxford Protein Production Facility, UK) as the base template. The open reading frames encoding PrP from diverse mammalian species — including bank vole (Myodes glareolus), mouse (Mus musculus), human (Homo sapiens), mule deer (Odocoileus hemionus), elk (Cervus canadensis), sheep (Ovis aries), and bottlenose dolphin (Tursiops truncatus) — were initially cloned into pOPIN E using standard molecular biology approaches. These wild-type constructs encompassed amino acids 23 to 231 (bank vole numbering), corresponding to the mature PrP lacking the N-terminal signal peptide.

[0242] To generate the comprehensive panel of PrP variants examined in this study, site-directed mutagenesis was performed by GenScript (Piscataway, NJ, USA) using the appropriate species-specific wild-type pOPIN E constructs as templates. The mutagenesis strategy encompassed three categories of modifications: (i) single amino acid substitutions to assess the impact of specific residues on misfolding propensity; (ii) insertions of one to twenty-six threonine residues at position 193 (bank vole numbering) or equivalent positions in other species, as well as insertions of alternative amino acids to evaluate sequence specificity; and (iii) deletions within the poly-threonine region and flanking sequences to identify critical structural determinants. Additional variants included modifications to the conserved tetrathreonine motif (TTTT - SEQ ID NO: 1) through amino acid substitutions at specific positions while maintaining or removing the protective threonine insertion.

[0243] All plasmid constructs generated by GenScript were sequence-verified by Sanger sequencing across the entire PrP open reading frame to confirm the intended mutations and exclude undesired secondary alterations. Sequence-confirmed plasmids were subsequently used for recombinant protein expression.

[0244] Recombinant protein expression and purification

[0245] Sequence-verified pOPIN E expression vectors were transformed into E. coli Rosetta (DE3) competent cells (Novagen, EMD Millipore) via heat-shock transformation. Transformed colonies were selected on LB agar plates supplemented with 100 pg / mlampicillin (Sigma-Aldrich) and used to inoculate overnight starter cultures in LB medium containing the same antibiotic concentration.

[0246] For large-scale protein production, overnight cultures were diluted 1:100 into fresh LB medium with 100 pg / ml ampicillin and grown at 37 °C with orbital shaking at 220 rpm until reaching an optical density (ODeoo) of 0.6-0.8. Recombinant protein expression was induced by addition of isopropyl p-D-1 -thiogalactopyranoside (IPTG; Gold Biotechnology) to a final concentration of 1 mM, and cultures were incubated for additional 3-4 hours at 37 °C with continued shaking. Bacterial cells were harvested by centrifugation at 4,500 g for 20 min at 4 °C.

[0247] Cell pellets were resuspended in lysis buffer [50 mM Tris-HCI pH 8.0, 5 mM EDTA, 1% (v / v) Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF)] supplemented with 100 pg / ml lysozyme (Sigma-Aldrich) and incubated on ice for 30 min. Following lysis, DNase I (100 U / ml; Sigma-Aldrich) and MgCh (20 mM final concentration) were added, and samples were incubated for 30 min at room temperature. Lysates were clarified by centrifugation at 8,500 g for 60 min at 4 °C and the resulting pellets were washed by resuspension in washing buffer [20 mM Tris-HCI pH 8.0, 150 mM NaCI, 1 mM EDTA, 1% (w / v) N-lauroylsarcosine] followed by centrifugation at 8,500 g for 60 min at 4 °C.

[0248] Washed inclusion body pellets were solubilized overnight at 37 °C with vigorous shaking in denaturing buffer containing 20 mM Tris-HCI pH 8.0, 500 mM NaCI, and 6 M guanidine hydrochloride (GdnHCI; Sigma-Aldrich). Solubilized protein solutions were clarified by centrifugation at 8,500 g for 60 min at 4 °C, followed by filtration through 0.22 pm syringe filters (Corning).

[0249] Recombinant proteins were purified using HisTrap FF Crude 5 ml columns (Cytiva, formerly GE Healthcare) coupled to an AKTA Start FPLC system (Cytiva). Columns were equilibrated with binding buffer [20 mM Tris-HCI pH 8.0, 500 mM NaCI, 2 M GdnHCI, 10 mM imidazole], and clarified protein lysates were loaded at a flow rate of 2-3 ml / min. Following extensive washing with binding buffer, recombinant PrP was eluted using elution buffer [20 mM Tris-HCI pH 8.0, 500 mM NaCI, 2 M GdnHCI, 500 mM imidazole]. Eluted fractions were pooled based on UV280 absorbance profiles.

[0250] The purity and integrity of recombinant protein preparations were assessed by SDS-PAGE followed by total protein staining with BlueSafe (NZYTech). Protein concentrations were determined by UV spectrophotometry at 280 nm using calculated extinction coefficients. GdnHCI concentration was adjusted to 6 M, and protein concentration was standardized to 25 mg / ml using Amicon Ultra-15 centrifugal filter units with 10 kDa molecular weight cutoff (Millipore). Purified proteins were aliquoted andstored at -80 °C in 6 M GdnHCI for long-term preservation until required for experimental procedures.

[0251] Preparation of cetacean brain substrates for PMCA

[0252] Brain tissue samples from 5 cetacean species representing PrP variants from different families were obtained from stranded animals through European marine mammal stranding networks. As these samples could not be perfused prior to collection, brain homogenates were prepared with modified conversion buffer supplemented with excess EDTA to compensate for higher blood content (Castilla J, Saa P, Soto C. Nat Med. 2005;11(9):982-985). Perfused brain tissues were processed to generate PrPc-containing substrates following established protocols (Fernandez-Borges N, et al. Prions, Methods and Protocols. Methods Mol Biol. 2017;1658:205-216). Whole brain samples were homogenized to a final concentration of 10% (weight / volume) in Conversion Buffer supplemented with complete protease inhibitor cocktail (Roche Diagnostics) using a glass-Teflon Potter-Elvehjem homogenizer (Fisher Scientific). Homogenates were distributed into working aliquots and maintained at -80 °C until use in PMCA experiments.

[0253] For the comprehensive resistance screening, brain homogenates were prepared from representatives spanning the major cetacean lineages: Tursiops truncatus (bottlenose dolphin, Delphinidae), Delphinus capensis (long-beaked common dolphin, Delphinidae), Balaenoptera physalus (Fin whale, Balaenopteridae), Grampus griseus (Risso's dolphin, Delphinidae) and Stenella coeruleoalba (striped dolphin, Delphinidae).. These species collectively represent >80% coverage of extant cetacean diversity across both Odontoceti and Mysticeti suborders. Additionally, brain homogenates from TgVole, Tg338, roe deer and TgBo110 were prepared in the same way to be used as positive propagation controls, for the selected inocula, described in the following section.

[0254] Brain-PMCA amplification and serial passage

[0255] PMCA amplification was conducted using a modified cyclic amplification protocol adapted from Castilla et al. (J Biol Chem. 2006;281(46):35245-35252) to evaluate convertibility of cetacean PrPcby mammalian prion strains. Initial PMCA reactions were seeded with well-characterized mouse-adapted scrapie strain RML, cervid chronic wasting disease agent (CWD), classical sheep scrapie SSBP / 1, and bovine spongiform encephalopathy (BSE), each diluted 1:10 into freshly prepared cetacean brain substrates.PMCA cycles were performed using a Misonix S-4000 microplate horn sonicator (Qsonica LLC) programmed for 30-min incubation intervals at 38 °C followed by 20-sec sonication pulses delivered at 80% amplitude. Temperature was maintained via a recirculating water bath throughout the procedure. To minimize potential crosscontamination between samples, individual reaction tubes were sealed with laboratory sealing film (Parafilm M) prior to each amplification cycle, and tube exteriors were decontaminated with 1% sodium hypochlorite solution between handling steps. Seeds from different prion strains were processed in separate batches. Each seeded sample underwent six consecutive rounds of serial PMCA amplification, with 1:10 dilution of amplified material into fresh substrate between rounds. All reactions included a single 1.0-mm zirconium-silicate bead (BioSpec Products). Negative control reactions containing unseeded substrate were subjected to identical amplification conditions alongside seeded samples throughout all six passages and positive controls, using brain homogenates of susceptible species as substrates (TgVole for RML, Tg338 for SSBP / 1, roe deer for CWD and TgBo110for BSE), were also included. Additionally, for each seed, a non-amplified control tube containing the initial 1:10 seed dilution was maintained to establish baseline PrPressignal. Amplification efficiency was assessed after each passage by proteinase K digestion followed by immunoblot detection as described in the PrPresdetection section below.

[0256] Generation of spontaneous recombinant prions by PMSA

[0257] The spontaneous misfolding propensity of all recombinant PrP variants generated in this study was systematically evaluated using Protein Misfolding Shaking Amplification (PMSA), a methodology we previously developed and optimized for consistent de novo generation of authentic recombinant prions (Eraha H, et al. Nat Commun.

[0258] 2024;15(1):2112). This approach enables quantitative assessment of the intrinsic tendency of distinct PrP sequences to undergo spontaneous conversion into proteaseresistant, amyloidogenic conformers in the absence of pre-existing prion seeds. The complete procedural details and optimization parameters for this technique have been described extensively in our prior work (Eraha H, et al. Nat Commun. 2024;15(1):2112).

[0259] Substrate preparation for PMSA reactions: Purified recombinant proteins were thawed and diluted 1:5 in phosphate-buffered saline (PBS; HyClone). Diluted proteins were then subjected to dialysis against PBS at a 1 :10,000 volume ratio for 1 hour at room temperature using appropriate molecular weight cutoff dialysis tubing. Following dialysis, samples were centrifuged at 19,000 g for 15 min at 4 °C to pellet any amorphous aggregates or insoluble material, and clarified supernatants containing properly refoldedrecombinant PrP were collected. Following dialysis, clarified supernatants were diluted 1:10 in conversion buffer (CB) supplemented with 0.5% (w / v) dextran sulfate sodium salt (molecular weight 6,500-10,000 Da; Sigma-Aldrich). For experiments requiring direct comparison of misfolding propensity across different PrP variants, protein concentrations in post-dialysis samples were quantified using the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific), and substrate concentrations were normalized prior to PMSA reactions. Final protein concentrations within standardized substrates were independently verified by SDS-PAGE followed by total protein staining with BlueSafe (NZYTech) to ensure equivalent loading across samples, as described below.

[0260] PMSA reaction conditions: Spontaneous prion formation assays were conducted in 2 ml screw-cap tubes containing 500-800 pl of freshly prepared substrate. To facilitate spontaneous PrP misfolding through surface-catalyzed nucleation, reaction tubes were supplemented with 200 mg of acid-washed glass beads. Two bead sizes were employed: 0.1 mm diameter glass beads (Sigma-Aldrich), and 1 mm diameter glass beads (BioSpec Products).

[0261] PMSA reactions were performed in programmable temperature-controlled orbital shakers (Digital Shaking Drybath, Thermo Scientific) maintained at 39 °C with continuous agitation at 700 rpm. Unless otherwise specified for particular experimental conditions, each PMSA round consisted of a 24-hour incubation period. The spontaneous misfolding propensity of each PrP variant was systematically quantified using a standardized scoring system based on the kinetics of rec-PrPresformation across multiple replicate tubes and serial PMSA rounds. Briefly, each variant was tested in replicate reactions using both 0.1 mm and 1 mm glass beads, with higher scores assigned to proteins generating detectable protease-resistant products in earlier rounds and under more restrictive conditions (smaller beads). Complete details of the scoring algorithm, including the number of replicates, serial round protocols, and statistical criteria for classification, have been described extensively in our prior methodological work (Eraha H, et al. Nat Common. 2024;15(1):2112).

[0262] Detection of protease-resistant misfolded recombinant PrP: Following PMSA reactions, samples were analyzed for the presence of proteinase K-resistant, misfolded recombinant PrP (rec-PrPres) using a standardized biochemical detection protocol. Aliquots of 400 pl from each PMSA reaction product were transferred to 1.5 ml microcentrifuge tubes and digested with proteinase K (PK; Roche) at a final concentration of 25 pg / ml for 1 hour at 42 °C in a standard laboratory incubator (Nahita). Proteolytic digestion was terminated by immediate centrifugation at 19,000 g for 15 minat 4 °C to pellet protease-resistant protein aggregates. Pellets were washed once with 500 pl PBS, followed by centrifugation at 19,000 g for 5 min at 4 °C. After removing the wash buffer, protease-resistant pellets were resuspended in 15 pl of 1x sample loading buffer (NuPAGE LDS Sample Buffer; Invitrogen).

[0263] For electrophoretic analysis, both PK-digested samples and undigested substrate controls were denatured by boiling at 100 °C for 10 min, then loaded onto 4-12% gradient polyacrylamide gels (NuPAGE Bis-Tris precast gels; Invitrogen). Electrophoresis was conducted using a three-stage voltage protocol: initial separation at 70 V for 10 min, followed by 110 V for 10 min, and final resolution at 150 V for 60 min. Following electrophoresis, gels were incubated with BlueSafe total protein stain (NZYTech) for a minimum of 1 hour at room temperature with gentle orbital agitation. Stained gels were imaged using a gel documentation system, and the presence of characteristic proteaseresistant fragments corresponding to the amyloid core of misfolded PrP (approximately 16-18 kDa for most mammalian PrP variants) was scored as positive evidence of spontaneous prion formation.

[0264] Seeded PMSA forevaluation of templated prion propagation

[0265] To assess whether the threonine insertion could block template-directed prion conversion, seeded PMSA experiments were conducted using established prion strains as seeds and recombinant PrP substrates with or without the threonine insertion. A homologous experimental design was employed in which seeds and substrates were derived from the same species to eliminate confounding effects from species transmission barriers.

[0266] The following species-strain combinations were tested: bank vole PrP seeded with strains Ust02 and Ust09 (Eraha H, et al. Acta Neuropathol Commun. 2023;11(1):145); mouse PrP seeded with strains btML90 and stMLOl (Perez-Castro MA, et al. PLOS Pathog. 2025;21(1):e1012890); mule deer PrP seeded with chronic wasting disease strains De-174C and De-174D (Diaz-Dominguez CM, et al. Neurobiol Dis.

[0267] 2025;213: 107005); elk PrP seeded with chronic wasting disease strains EI-399B and El-399C (Diaz-Dominguez CM, et al. Neurobiol Dis. 2025;213:107005); sheep PrP (VRQ genotype) seeded with strain ShVRQ9 and sheep PrP (ARQ genotype) seeded with strain ShARQI; and human PrP seeded with strains EGM-1-3 and EGM-0-2. For each species-strain combination, prion seeds were prepared as 10% (w / v) brain homogenates from terminally ill animals and serially diluted in PBS from 10'3to 10'8.Substrates were prepared as described in "Substrate preparation for PMSA reactions" and reactions were conducted following the conditions specified in "PMSA reaction conditions," with the modification that 1-mm diameter zirconia-silicate beads (BioSpec Products) were used instead of glass beads.

[0268] Unseeded control reactions containing substrate without prion seed were included for each recombinant PrP variant to confirm the absence of spontaneous aggregation during the seeded PMSA procedure.

[0269] Generation of transgenic mice expressing mouse PrP with threonine insertions

[0270] CRISPR-Cas9 genome editing strategy for single threonine insertion: To validate our in vitro findings in a living system, we generated knock-in mouse lines expressing mouse PrP carrying cetacean-derived threonine insertions at the T192_T193 site of the endogenous Prnp gene. A CRISPR-Cas9 genome editing approach was designed to introduce an extra threonine codon (ACA) insertion (into the conserved tetrathreonine motif in the mouse Prnp gene (corresponding to the insertion site identified in cetacean PrP sequences). The trans-activating crRNA (tracrRNA), a sequence-specific crRNA (5’-GGUGAAGUUCUCCCCCUUGG-3’ - SEQ ID NO: 144), and a 200-nucleotide singlestranded oligodeoxynucleotide (ssODN) template encoding the desired threonine insertion, with the inserted codon shown in bold lowercase within the sequence (5’-ACCAAGTGTACTACAGGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCA CGACTGCGTCAATATCACCATCAAGCAGCACACGGTCACCACCACCAcaaCCAAG GGGGAGAACTTCACCGAGACCGATGTGAAGATGATGGAGCGCGTGGTGGAGCAG ATGTGCGTCACCCAGTACCAGAAGGAGTCCCAGGCC-3’ - SEQ ID NO: 145), were chemically synthesized (Integrated DNA Technologies) for targeting the insertion site within Prnp exon 3. The mature single-guide RNA (sgRNA) complex was assembled in vitro by combining equimolar concentrations of crRNA and tracrRNA, followed by thermal annealing through a controlled heating and cooling protocol to ensure stable duplex formation. The editing mixture — containing mature sgRNA (20 ng / pl), recombinant Cas9 nuclease protein (30 ng / pl), and ssODN repair template (10 ng / pl) — was introduced into the pronuclei of fertilized F1 hybrid zygotes via microinjection.

[0271] Mouse strains, embryo harvest and microinjection procedures: T o optimize embryo yield, quality and viability for microinjection, we employed a breeding strategy involving crosses between wild-type B6J / CBA female mice and homozygous males from the previously established BQ / CB / -Prnpem1<c-322C>A)Msamknock-in mouse line (named hereas TgMo(L108l)1x31). This crossing scheme was selected to generate F1 hybrid zygotes with optimal developmental competence for microinjection while simultaneously introducing the L108I allele required for the experimental prion models. The crossing scheme generated 50% of F1 heterozygous zygotes carrying the Prnp TgMo(L108l)1x male allele and the wild-type Prnp allele inherited from the B6J / CBA female. This line carries the substitution of leucine 108 to Isoleucine that accelerates prion disease progression (Eraha H, et al. Brain Pathol. Published online 2026. doi: 10.1111 / bpa.70083). The crossing scheme generated a 50% of F1 heterozygous zygotes with the Prnp TgMo(L1081)1 x male allele and the PrnP wildtype allele inherited from B6 / CBA female. Briefly, the editing CRISPR mixture designed to target the conserved tetrathreonine motif was introduced into the pronuclei of fertilized F1 hybrid zygotes via microinjection.

[0272] Surviving embryos were implanted into pseudopregnant recipient females and pups were weaned at postnatal day 21. All embryo manipulation procedures were performed at the Transgenic Facility of the Institute for Biomedical Research of Salamanca (IBSAL) and University of Salamanca following a standardized workflow (Sanchez-Martin M, et al. Meiosis, Methods and Protocols. Methods Mol Biol.

[0273] 2024;2818:93-112).

[0274] Genotyping and molecular validation of edited founders: Genomic DNA was isolated from ear biopsy samples of offspring using the QIAamp DNA Mini Kit (QIAGEN) according to the manufacturer's tissue protocol. DNA yield and purity were assessed by spectrophotometry on a NanoVue Plus instrument (GE Healthcare), measuring absorbance at 260, 280, and 230 nm. Sample integrity was confirmed by agarose gel electrophoresis using 1.5% gels prepared in 1x TAE buffer (Thermo Fisher Scientific) and visualized under ultraviolet illumination.

[0275] Amplification and sequencing of the complete Prnp open reading frame: To comprehensively characterize editing outcomes at both position 108 (leucine vs. isoleucine) and position 192 (threonine insertion status), we designed primers to amplify the entire Prnp coding sequence. Primer design was conducted using FastPCR software (version 3.3.67) and NCBI Primer-BLAST to optimize thermodynamic properties and ensure target specificity. Both forward and reverse primers incorporated M13 sequencing tails at their 5' termini (shown in italics) to facilitate standardized Sanger sequencing workflows: FM13_PRNP (5- TGTAAAACGACGGCCAGTAGCGGCCAAAGCCTGGAGG-3' - SEQ ID NO: 146) andRM13_PRNP (5'-CAGGAAACAGCTATGACCTCCCACGATCAGGAAGATGAGG-3' -SEQ ID NO: 147).

[0276] PCR amplifications were performed in 10 pl reaction volumes containing: 5.75 pl nuclease-free water, 1.0 pl 10x NH4 reaction buffer, 0.4 pl MgCh (50 mM stock, 2 mM final), 0.25 pl dNTP mix (100 mM stock, 2.5 mM final), 1.5 pl primer mix (2.5 pM each primer, 0.375 pM final perprimer), 0.1 pl BIOTAQ DNA polymerase (Bioline; 5 ll / pl stock, 0.5 II per reaction), and 2.0 pl genomic DNA template. Optimal annealing temperature was determined empirically using gradient PCR (50-65 °C) with pooled DNA from multiple animals; subsequent amplifications employed an annealing temperature of 65 °C.

[0277] Amplified products were enzymatically purified using ExoSAP-IT (Exonuclease I and Shrimp Alkaline Phosphatase treatment: 37 °C for 15 min, followed by heat inactivation at 80 °C for 15 min) and subjected to bidirectional Sanger sequencing using BigDye Terminator v3.1 chemistry on an ABI 3500 Genetic Analyzer (Thermo Fisher Scientific).

[0278] Allele-specific discrimination of L108 versus 1108 genetic backgrounds: Initial sequencing analysis revealed that many founders harbored mosaic or compound heterozygous genotypes at the edited locus, likely resulting from CRISPR-Cas9 activity persisting through multiple cell divisions during early embryogenesis. To unambiguously assign threonine addition events to either the leucine-108 or isoleucine-108 allelic background, we developed allele-specific PCR assays exploiting single nucleotide discrimination. Forward primers were designed with the discriminating base positioned at the 3' terminus (shown in bold): FM13_PRNP_Leu108 (5-AGCAAACCAAAAACCAACC-3' - SEQ ID NO: 148, specific for leucine codon CTC) and FM13_PRNP_lle108 (5-AGCAAACCAAAAACCAATA-3' - SEQ ID NO: 149, specific for isoleucine codon ATC). Both reactions utilized the common reverse primer RM13_PRNP.

[0279] Allele-specific amplifications were conducted in separate reactions using the following thermal profile: initial denaturation at 95 °C for 5 min; 35 cycles of 95 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 30 sec; final extension at 72 °C for 10 min. Each allele-specific product was purified with ExoSAP-IT and independently sequenced on an ABI 3500 Genetic Analyzer. Electropherograms were analyzed using Sequencing Analysis software v5.4 (Thermo Fisher Scientific).

[0280] Selection criteria and breeding strategy for colony establishment: Genome sequence analysis of F0 mosaic founders revealed several animals carrying distinctmodified alleles, including two L108I alleles with threonine insertions: the intended single threonine insertion, and a subset of founders carrying a tandem double threonine insertion at the same site. This unanticipated double insertion likely arose from template slippage or iterative repair events during homology-directed repair, facilitated by the repetitive nature of the tetrathreonine-encoding region (ACC ACC ACC ACC - SEQ ID NO: 150).

[0281] From the pool of mosaic founders, we selected animals carrying one allele with the L108I substitution combined with either the single threonine insertion p.T192_T193insT — hereafter TgMo(L108l lns192T)1x — or the tandem double threonine insertion p.T192_T193insTT — hereafter TgMo(L108l lns192TT)1x. These founders were backcrossed to the parental TgMo(L108l)1x homozygous line to segregate the desired allele and dilute potential off-target mutations. Heterozygous offspring were re-genotyped using the allele-specific sequencing pipeline described above. Following validation, heterozygous animals were intercrossed to generate homozygous offspring. Two independent breeding colonies were established on a mixed B6J / CBA genetic background:

[0282] 1. TgMo(L108l lns192T)1x — mouse PrP carrying the L108I substitution plus a single threonine insertion ^B6J / CBA-Prnpem1(c-322C>A:a573-574insACA)Msarn).

[0283] 2. TgMo(L108l lns192TT)1x — mouse PrP carrying the L108I substitution plus a tandem double threonine insertion (B6J / CBA- Pm pem(c-322C>A;c.573_574insACAACC)MsanT

[0284] Homozygous animals from both lines exhibited normal viability, fertility, and behavior under standard housing conditions, indicating that threonine insertions do not compromise essential PrP functions. The serendipitous generation of the double insertion line proved particularly valuable, as it enabled direct in vivo comparison of dosedependent protective effects conferred by single versus tandem threonine insertions against multiple prion strains.

[0285] In vivo transmission experiments

[0286] Brain homogenates for primary passage experiments: Three well-characterized mouse-adapted scrapie strains were selected for in vivo transmission studies: RML, 22L, and ME7. Primary inocula were prepared from terminal-stage brain tissue obtained from prion-infected wild-type mice maintained at CIC bioGUNE and originally sourced from the TSE Resource Centre (Compton, Newbury, UK). For each strain, whole brains were harvested from terminally ill animals, pooled when appropriate, and mechanicallyhomogenized using glazed porcelain mortar and pestle in ice-cold phosphate-buffered saline (PBS; Fisher Reagents) supplemented with Complete Protease Inhibitor Cocktail (Roche) to yield 10% (w / v) stock homogenates. Stock preparations were aliquoted and stored at -80 °C. Immediately prior to intracerebral inoculation, frozen aliquots were thawed on ice and diluted to 1% (w / v) in sterile Dulbecco's PBS (DPBS; Gibco).

[0287] Brain homogenates for serial passage experiments: For second passage transmissions, inocula were prepared from individual animals that had succumbed to prion disease during primary passage experiments in either TgMo(L108l lns192T)1x or TgMo(L108l lns192TT)1x mice. Brain tissue was processed using the identical homogenization protocol described above, generating 10% (w / v) stock homogenates that were subsequently diluted to 1 % (w / v) in DPBS for inoculation. When possible, brain tissue was selected from animals whose incubation periods approximated the group mean to ensure representative prion populations. These serially passaged materials were designated according to their passage history (e.g., RML adapted in TgMo(L108l lns192T)1x mice after primary passage).

[0288] Inoculation procedure: Experimental cohorts of transgenic mice — comprising TgMo(L1081)1 x (baseline control model), TgMo(L108l lns192T)1x (single threonine insertion), and TgMo(L108l lns192TT)1x (double threonine insertion) — were inoculated at 6-8 weeks of age. Group sizes and specific experimental conditions for each prion strain are detailed in the Results section. Animals were anesthetized using either isoflurane inhalation anesthesia (IsoVet; Braun) or, when necessary, injectable ketamine / medetomidine combination (75 / 1 mg / kg; Imalgene 1000, Boehringer Ingelheim / Domtor, Ecuphar) with subsequent reversal using atipamezole hydrochloride (1 mg / kg; Antisedan, Ecuphar).

[0289] Following anaesthetic induction, a volume of 20 pl of 1% (w / v) brain homogenate inoculum was delivered into the right cerebral hemisphere at approximately 3 mm depth using a sterile 27-gauge hypodermic needle attached to a precision microsyringe (Terumo). To prevent inoculum reflux along the injection tract, the needle was maintained in position for 30 seconds before gradual withdrawal.

[0290] Post-inoculation housing and clinical monitoring: Following inoculation, mice were group-housed (4-6 animals per cage) in individually ventilated caging systems maintained under controlled environmental conditions: 22 °C ambient temperature, 12-hour light / dark cycle, and 60% relative humidity. Animals had ad libitum access to standard laboratory chow and water. General health assessments were performed daily, with detailed neurological examinations conducted twice weekly until the emergence ofclinical signs consistent with prion disease, upon which monitoring frequency was increased to daily evaluations.

[0291] Clinical manifestations of prion disease were systematically documented using standardized criteria including: progressive kyphosis, gait ataxia or incoordination, piloerection or unkempt coat, behavioral depression or reduced responsiveness, postural abnormalities, ocular discharge or crusting, stereotypic behaviors or hyperexcitability, progressive weight loss or cachexia, and urinary or fecal incontinence. Animals exhibiting two or more severe neurological signs, invalidating motor disturbances that compromised locomotion or feeding ability, or body condition scores indicating significant welfare compromise were humanely euthanized to prevent unnecessary suffering.

[0292] Humane endpoints and tissue collection: Terminal animals were euthanized by exposure to gradually increasing concentrations of carbon dioxide in accordance with institutional animal welfare guidelines. Incubation periods were calculated as the interval from inoculation to euthanasia or spontaneous death, expressed as days postinoculation (dpi). Immediately following euthanasia, brains were rapidly extracted and bisected along the sagittal midline. One hemisphere was immersion-fixed in 10% neutral-buffered formalin (Sigma-Aldrich) for subsequent histopathological and immunohistochemical analyses, while the contralateral hemisphere was snap-frozen on dry ice and stored at -80 °C for biochemical characterization of PrPresaccumulation. Attack rates were calculated as the proportion of animals developing laboratory-confirmed prion disease — defined by positive PrPresdetection via Western blot and / or immunohistochemistry — relative to the total number inoculated within each experimental group. Animals succumbing to intercurrent illnesses unrelated to prion pathology or exhibiting non-specific pathology prior to reaching 50% of their cohort's median incubation period, were excluded from survival and attack rate calculations but documented separately. Incubation period data are reported as group mean ± standard error of the mean (SEM), with individual animal data provided in source data files.

[0293] PrPresdetection by electrophoresis and Western blot

[0294] For PrPresanalysis, brain tissue from inoculated animals was homogenized at 10% (w / v) in PBS (Fisher Bioreagents) supplemented with protease inhibitor cocktail (Roche). Homogenates were mixed 1:1 (v / v) with a digestion buffer containing 2% (w / v) Tween-20 (Sigma-Aldrich), 2% (v / v) NP-40 (Sigma-Aldrich), and 5% (w / v) Sarkosyl (Sigma-Aldrich) in PBS, and treated with proteinase K (Roche) to a final concentration of 80 pg / mL. Samples were incubated for 1 h at 42 °C with shaking at 450 rpm in athermomixer (Eppendorf), after which digestion was stopped by adding NuPAGE 4x Loading Buffer (Invitrogen Life Technologies) at 1:3 (v / v) and boiling for 10 min at 100 °C. PK-digested samples, together with undigested controls, were resolved on 4-12% NuPAGE Midi gels (Invitrogen Life Technologies) for 1 h 20 min (70 V for 10 min, 110 V for 10 min, and 150 V for 1 h) and transferred to PVDF membranes using the iBIot™ 3 system (Invitrogen Life Technologies). Membranes were processed on an iBind™ Flex Western Device (Invitrogen Life Technologies) and probed with the Sha31 monoclonal antibody (Cayman Chemical; 1:4,000), followed by an HRP-conjugated anti-mouse secondary antibody (m-IgGK BP-HRP; Santa Cruz Biotechnology). Signals were developed using enhanced chemiluminescence (West Pico Plus, Thermo Scientific), acquired with an iBright™ CL750 imaging system (Invitrogen Life Technologies), and processed with AlphaView software (Alpha Innotech).

[0295] Histopathological and immunohistochemical analysis

[0296] Tissue preparation and sectioning: Following euthanasia, one brain hemisphere from each animal was immersion-fixed in 10% neutral-buffered formalin (Sigma-Aldrich) for 24-48 hours at room temperature. Fixed tissues were sectioned transversely at the levels corresponding to the medulla oblongata, piriform cortex, and optic chiasm regions to ensure comprehensive sampling of brain structures along the rostro-caudal axis. Tissue sections underwent routine histological processing consisting of sequential dehydration through graded ethanol concentrations (70%, 96%, and 100%), clearing in xylene, and infiltration with molten paraffin wax under vacuum. Processed tissues were embedded in paraffin blocks and sectioned at 4 pm thickness using a rotary microtome.

[0297] Serial sections were mounted on two slide types depending on application: standard glass microscopy slides for routine hematoxylin and eosin (H&E) staining to assess general neuropathological features; and silanized glass slides pre-coated with 3-triethoxysilylpropylamine (DAKO) to enhance tissue adherence during the immunohistochemical processing required for prion protein detection.

[0298] Immunohistochemical detection of disease-associated PrP: Visualization of protease-resistant, disease-associated prion protein (PrPres) required extensive antigen retrieval protocols to unmask epitopes within the highly aggregated protein deposits. Paraffin sections were first deparaffinized in xylene and rehydrated through descending ethanol concentrations to water. Epitope retrieval was achieved through immersion in 98% formic acid for 15 minutes to partially denature aggregated protein and inactivate residual infectivity.Following antigen retrieval, endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in methanol for 30 minutes at room temperature. Non-specific antibody binding sites were blocked through incubation with 10% normal goat serum in PBS containing 0.1% Triton X-100 for 30 minutes at room temperature.

[0299] Primary antibody incubation was performed overnight at 4°C in humidified chambers using anti-PrP mouse monoclonal antibodies. The specific antibody employed varied according to experimental requirements: 2G11 (1:100; Bio-Rad / Bertin Pharma) was used as the primary detection antibody for most experimental groups, while 6C2 (1:1000; CVI-Wageningen UR) was employed in selected cohorts for comparative assessment or when enhanced sensitivity was required. Following extensive washing in PBS, sections were incubated with polymer-conjugated anti-mouse secondary antibodies coupled to horseradish peroxidase (EnVision system; DAKO) for 30 minutes at room temperature. Immunoreactive sites were visualized using 3,3'-diaminobenzidine (DAB; DAKO / Sigma-Aldrich) as chromogenic substrate. Sections were counterstained with hematoxylin to visualize cellular nuclei, dehydrated through graded alcohols, cleared in xylene, and coverslipped using DPX mounting medium (Sigma-Aldrich). Negative controls consisting of sections processed identically but with omission of primary antibody were included in each staining run to assess background reactivity.

[0300] Neuropathological scoring and analysis: Histopathological evaluation of spongiform degeneration, and neuronal loss in H&E-stained sections, as well as semi-quantitative assessment of PrPresimmunolabeling intensity and distribution patterns, were performed by an experienced neuropathologist under blinded conditions with respect to experimental group assignments. Fourteen neuroanatomical regions were systematically evaluated across the rostro-caudal neuraxis: piriform cortex (Pfc), hippocampus (H), occipital cortex (Oc), temporal cortex (Tc), parietal cortex (Pc), frontal cortex (Fc), striatum (S), thalamus (T), hypothalamus (HT), mesencephalon (M), medulla oblongata (Mob), cerebellar nuclei (Cm), cerebellar vermis (Cv), and cerebellar cortex (Cc).

[0301] For each region, spongiform vacuolation and PrPresimmunoreactivity were independently scored using a five-point semi-quantitative scale: from 0 (complete absence of pathological changes or immunolabeling) to 4 (severe pathology with confluent vacuolation or intense diffuse immunoreactivity throughout the region). Each brain region was evaluated globally and assigned a single representative score reflecting the predominant pathological severity within that anatomical area.Lesion distribution profiles were constructed by plotting mean scores for spongiform change and PrPresdeposition across the fourteen brain regions arranged sequentially from caudal to rostral neuroanatomical structures. Profile data were generated using Microsoft Excel software and are presented as line graphs with brain regions displayed along the x-axis and mean severity scores along the y-axis. Error bars represent the standard error of the mean (SEM).

[0302] Structural determination by NMR spectroscopy

[0303] Uniformly15N-13C-labelled human prion protein (PrP residues 90-231) with a double threonine insertion (T192_T193lnstTT) was prepared at concentrations of -200 pM in 20 mM sodium acetate buffer (pH 5.5), 150 mM NaCI, 0.05 % NaN3, and 10 % (v / v) D2O. NMR data were acquired at 298 K on a Bruker Avance III 800 MHz spectrometer equipped with a triple-resonance1H / 13C / 15N cryogenic probe at the CIC bioGUNE NMR platform. Two-dimensional1H-15N HSQC and1H-13C HSQC spectra were initially recorded to assess sample quality, folding state, and spectral dispersion. Backbone resonance assignments were obtained using standard three-dimensional triple-resonance experiments, including HNCO, HNCA, HNcoCA, HNCACB, HNcoCACB, and HNcaHA. Side-chain assignments were completed using HccoNH, HNCCcoNH, and HCCH-TOCSY-based experiments. Distance restraints were derived from 3D15N-NOESY-HSQC and13C-NOESY-HSQC spectra recorded with a mixing time of 120 ms. Where appropriate, non-uniform sampling (NUS, 25-35 %) was employed to optimise spectrometer time while maintaining spectral resolution. All spectra were acquired using TopSpin 4.2 (Bruker). Raw data were processed with NMRPipe 12.2 (Delaglio F, et al. J Biomol NMR. 1995;6(3):277-293), and resonance assignment as well as restraint analysis were performed using CCPNMR 3.3.4 Analysis (Skinner SP, et al. J Biomol NMR. 2016;66(2):111-124). Chemical shifts were referenced indirectly to DSS.

[0304] Structure calculations were carried out using XPLOR-NIH 3.11 (Schwieters CD, et al. Prog Nucl Magn Reson Spectrosc. 2006;48(1):47-62) with torsion-angle dynamics. NOE-derived distance restraints were extracted and classified following standard procedures. For each variant, 200 structures were generated per calculation cycle starting from randomised conformations. The lowest-energy conformers without significant distance or dihedral-angle violations were selected to form the final structural ensemble. Final refinement was performed in explicit solvent using the same software. The quality of the resulting ensembles was assessed by analysis of NOE and dihedralangle violations, backbone and heavy-atom RMSD values, and Ramachandran statisticsusing PROCHECK-NMR (Laskowski RA, et al. Published online 2013:684-687) MolProbity (Williams CJ, et al. Protein Sci. 2018;27(1):293-315) and wwPDB validation software. Molecular graphics and figures were prepared using PyMOL 3.1.

[0305] Chemical shifts and structure coordinates have been deposited in the BioMagResBank (BMRB accession number 35030) and the Protein Data Bank (PDB ID: 9TVY) (Table 3)

[0306] Table 3. Structural statistics for the NMR ensemble of human prion protein T192_T193lnstTT. Values are reported for the 10 lowest-energy conformers after explicit-solvent refinement.

[0307] Parameter Value

[0308] Protein Human PrP (residues 90-231),

[0309] T192_T193lnstTT

[0310] Number of models deposited 10

[0311] Backbone RMSD (Core residues) 0.53 A

[0312] Heavy-atom RMSD (Core residues) 1.12 A

[0313] Dihedral angle restraints 196

[0314] Total NOE-derived distance restraints 2739

[0315] - Intra-residue (|i-j| = 0) 1277

[0316] - Sequential (|i-j| = 1) 890

[0317] - Medium-range (1 < |i-j| < 4) 300

[0318] - Long-range (|i-j| > 4) 272

[0319] Restraints per residue 18.1

[0320] Ramachandran favoured residues 96 ± 1 %

[0321] Ramachandran allowed residues 4 ± 1 %

[0322] Ramachandran outliers 1 ± 0 %

[0323] Chemical shift assignment completeness 82 %

[0324] Accession codes BMRB 35030; PDB 9TVY

[0325]

[0326] Computational modelling

[0327] AlphaFold3 predictions of PrPc: AlphaFold3 structure predictions were performed with codebase version 3.0.0.( Abramson J, et al. Nature. 2024;630(8016):493-500) AlphaFold3 outputs structural models in CIF format without hydrogen atom coordinates. To facilitate analysis and visualization, the models were converted to PDB format using a two-step protocol: first, CIF files were converted to PDB using Open Babel (O’BoyleNM, et al. J Cheminformatics. 2011;3(1):33); then, hydrogen atoms were added using tleap from the AmberTools suite (Case DA, et al. AmberTools. J Chem Inf Model.

[0328] 2023;63(20):6183-6191).

[0329] Fibril models: For each strain, three fibril models were generated: wild-type, a model with a single threonine insertion [lns192T (p.T192_T193insT)], and a mixed model containing both wild-type and lns192T monomers. All models are composed of 12 monomers, and mixed fibrils contain a 1:1 ratio of wild-type and lns192T with a single wild-type / lns192T interface. Atomic coordinates for the wild-type fibrils were taken from the cryo-EM structures of the 22L and RML strains deposited in the RCSB PDB (PDB IDs: 8EFLI and 7QIG, respectively). Atomic coordinates for the lns192T monomers were generated from the same coordinates through homology modelling.

[0330] Homology modelling: Modelling of single threonine insertion was performed using the Prime application in Schrodinger Maestro Suite (Jacobson MP, et al. Proteins: Struct, Fund, Bioinform. 2004;55(2):351-367, Jacobson MP, et al. J Mol Biol. 2002;320(3):597-608). Templates were retrieved from the RCSB PDB database (PDB ID 8EFLI for the 22L fibril and PDB ID 7QIG for the RML fibril). Homology modelling was carried out using the knowledge-based model-building algorithm in Prime, generating a single structural model.

[0331] Molecular dynamics: All-atom MD simulations were carried out with AMBER24 (Case DA, et al. Amber 2024. California II of, eds. Covers Amber24 and AmberTools24. Published online December 18, 2024) using the ff14SB force field for the fibrils (Maier JA, et al. J Chem Theory Comput. 2015;11(8): 3696-3713) and the TIP3P force field (Jorgensen WL, et al. J Chem Phys. 1983;79(2):926-935) for water. Oligomeric models consisting of twelve monomers were generated through replication via translational symmetry of the cryo-EM structures, which contain three monomers each. The Cartesian coordinates of the dodecameric models were oriented such that the fibril growth axis is aligned with the z-axis and immersed in a water box with a 20 A buffer of water molecules and neutralized by adding explicit Cl’ counter ions (Li-Merz 12-6 normal usage set (Li P, et al. J Chem Theory Comput. 2015;11(4):1645-1657). Water molecules exceeding the z-coordinate values of the fibril were trimmed and the box parameter along the z-axis adjusted to match the ideal p-sheet separation (58.589 A, corresponding to a 4.882 A inter-rung separation). Under these conditions, simulations were run employing periodic boundary conditions; in this way, the dodecameric model in the reference cell interacts with its periodic images simulating a fibril of infinite length. This setup prevents edge effects that would otherwise promote oligomer disaggregation and has been previouslyapplied to the study of amyloid systems (Buchete NV, et al. Biophys J. 2007; 92(9): 3032-3039).

[0332] The system was subjected to geometry optimization using 5,000 steps of steepest descent followed by 5,000 steps of conjugate gradient minimization. Subsequently, it was heated from 0 to 300 K over a 100 ps simulation in the NVT ensemble using a Langevin thermostat48. This was followed by an unrestricted 4 ns molecular dynamics simulation in the NPT ensemble to equilibrate the system.

[0333] Production simulations were carried out in the NPT ensemble, employing anisotropic scaling and the Berendsen barostat (Berendsen HJC, et al. J Chem Phys.

[0334] 1984;81(8):3684-3690). The SHAKE algorithm (Miyamoto S, et al. J Comput Chem.

[0335] 1992;13(8):952-962) was used to constrain bonds involving hydrogen atoms, allowing a 2 fs integration time step. Long-range electrostatics were treated using the particle mesh Ewald method, with a nonbonded interaction cutoff of 10 A and a nonbonded list “skin” of 5.0 A (Darden T, et al. J Chem Phys. 1993;98(12): 10089-10092). Production was run as a 1 ps trajectory for each fibril model. Analysis was performed with cpptraj (Roe DR, et al. J Chem Theory Comput. 2013;9(7):3084-3095).

[0336] Statistics and reproducibility

[0337] Experimental design and sample sizing: Animal group sizes for prion transmission bioassays were determined based on established practices in prion research and prior experience with comparable transgenic mouse models. Experimental cohorts comprised 5-7 animals per group, consistent with standard prion bioassay protocols. Specific group sizes for each experimental condition are detailed in the Results section and corresponding data tables.

[0338] Statistical analysis: Incubation period data are presented as group mean ± standard error of the mean (SEM), with individual animal survival times provided in source data files. Statistical comparisons of survival distributions between transgenic mouse lines were performed using log-rank (Mantel-Cox) tests. Attack rates were calculated as the proportion of animals developing laboratory-confirmed prion disease (defined by positive PrPresdetection via Western blot and / or immunohistochemistry) relative to the total number inoculated. Animals succumbing to intercurrent illnesses unrelated to prion pathology, or developing non-specific pathology prior to reaching 50% of their cohort's median incubation period, were excluded from incubation period calculations but are documented separately. Statistical significance was defined as P <0.05. All statistical analyses were performed using GraphPad Prism software (version 9.0 or later; GraphPad Software Inc.).

[0339] Reproducibility and blinding: Histopathological evaluation of spongiform degeneration and immunohistochemical assessment of PrPresdeposition were performed by an experienced neuropathologist under blinded conditions with respect to experimental group assignments. For PMSA experiments, recombinant PrP variants that failed to generate detectable protease-resistant products across all replicates (misfolding score = 0) were subjected to complete experimental replication to confirm results. Negative controls for immunohistochemical staining consisted of tissue sections processed identically but with primary antibody omission. Complete details of the PMSA scoring algorithm have been described previously (Eraha H, et al. Nat Commun.

[0340] 2024;15(1):2112).

[0341] RESULTS

[0342] Cetaceans display universal resistance to spontaneous prion misfolding In our comprehensive analysis of prion protein misfolding susceptibility across mammalian species, we observed a remarkable pattern among members of the order Cetacea. As reported in our recent large-scale screening (Eraha H, et al. Nat Commun.

[0343] 2024;15(1):2112), all tested cetacean species exhibited complete resistance to spontaneous misfolding in the Protein Misfolding Shaking Amplification (PMSA) assay, uniformly scoring 0 on our established misfolding propensity scale.

[0344] To contextualize this finding, we conducted a phylogenetic analysis of the order Cetacea, comprising both toothed whales (Odontoceti) and baleen whales (Mysticeti). Our sampling covered a substantial portion of cetacean biodiversity: 70% of all known cetacean species (62 out of 90), 95% of all genera (38 out of 40), and representatives from every extant cetacean family. This extensive taxonomic coverage provides strong evidence that resistance to spontaneous prion misfolding is a conserved trait across the entire cetacean lineage.

[0345] The consistent misfolding score of 0 observed in all tested cetacean species stands in stark contrast to the variable scores recorded across other mammalian orders, where susceptibility to spontaneous misfolding ranged from high (score 100, equivalent to bank vole PrP) to moderate and low. Detailed information on each tested cetacean species, including their sequences, predicted structures, and experimental results, can be accessed in the comprehensive PrP database, PrPdex (www.prpdex.com).

[0346] Brain-PMCA confirms the resistance of cetacean PrP to propagation of diverse prion strainsTo validate the spontaneous misfolding resistance observed in our previous PMSA screening, we sought to determine whether cetacean prion proteins are capable of propagating prions in a more stringent in vitro system. We employed brain-PMCA, a powerful technique that has previously demonstrated the ability to overcome transmission barriers considered insurmountable in in vivo systems (Chianini F, et al. Proc Natl Acad Sci. 2012;109(13):5080-5085; Bian J, et al. Proc Natl Acad Sci.

[0347] 2017;114(5):1141-1146; Fernandez-Borges N, et al. PLoS Pathog.

[0348] 2017;13(11):e1006716).

[0349] We obtained brain tissues from five representative cetacean species spanning multiple families: bottlenose dolphin (Tursiops truncatus, Delphinidae), long-beaked common dolphin (Delphinus capensis, Delphinidae), fin whale (Balaenoptera physalus, Balaenopteridae), striped dolphin (Stenella coeruleoalba, Delphinidae), and Risso's dolphin (Grampus griseus, Delphinidae). These brains were processed to create PMCA substrates and challenged with a diverse panel of prion seeds representing multiple species and disease phenotypes: mouse-adapted scrapie strain RML, bovine spongiform encephalopathy (BSE), classical sheep scrapie strain SSBP / 1, and chronic wasting disease (CWD) from cervids.

[0350] Given that the cetacean brain samples were obtained from stranded animals and could not be perfused, we modified our PMCA protocol by including excess EDTA in the conversion buffer, which has been shown to improve the efficiency of substrates with higher blood content (Castilla J, etal. Nat Med. 2005;11(9):982-985). To control for these non-standard conditions, we employed non-perfused transgenic bank vole [TgVole(l109)1x] brain homogenate as positive control for RML propagation, and TgBo110 transgenic cattle brain homogenate (Castilla J, et al.. Arch Virol.

[0351] 2003;148(4):677-691) as positive control for BSE, as well as a Tg338 brain and a roe deer brain for SSBP1, and CWD, respectively, given their known permissiveness to these prion strains.

[0352] The PMCA reactions were conducted in quadruplicate for each substrate-seed combination, with six serial rounds of 48-hour amplification and 1:10 dilutions between rounds. After six rounds, a striking pattern emerged: while all control reactions using TgVole, TgBo110, Tg338 and roe deer brain homogenates showed robust PrPrespropagation, none of the cetacean brain substrates displayed any detectable PrPresregardless of the prion seed used (Figure 9).

[0353] Sequence alignment reveals a unique threonine insertion in cetacean PrP as the key determinant of misfolding resistanceTo understand the molecular basis of the observed resistance to prion propagation in cetaceans, we performed comprehensive sequence analyses of all cetacean prion proteins tested in our PMSA assay (all with score 0). We aligned these sequences with PrP sequences from other mammals with varying misfolding propensities, focusing on the structured region starting from position 90, which forms the core of the proteaseresistant fragment in misfolded prion protein.

[0354] This alignment revealed two consistent differences unique to cetacean PrP sequences: (1) an absence of asparagine at a position conserved in most mammalian PrP sequences (equivalent to Asn104 in the human PrP), and (2) an insertion of threonine at p.(Thr196_Lys198insThr). Strikingly, while examining over 900 mammalian species from our database, we observed that the 104N deletion also occurs in a subset of artiodactyl species, but the ins196T is exclusively found in cetaceans. In fact, insertions and deletions in the core region of PrP (residues 90-220) are exceedingly rare across mammalian PrP sequences, making these cetacean-specific modifications particularly noteworthy.

[0355] To determine which of these two sequence alterations confers resistance to prion misfolding, we conducted a series of targeted mutagenesis experiments. First, we introduced the p.(Asn104del) into bank vole PrP, our gold standard substrate with high misfolding propensity (score 100). The resulting variant maintained robust misfolding ability in PMSA with a score identical to wild-type bank vole PrP. This finding is consistent with observations from other species that naturally possess the 100N deletion (bank vole numbering), such as some artiodactyls (Hippopotamus amphibious and Hexaprotodon liberiensis), which retain misfolding propensity in our assays [(1359, 0946 in the PrPdex database (www.prpdex.com)].

[0356] Conversely, when we introduced the T193_T194lnstT (bank vole numbering) modification into bank vole PrP, the misfolding propensity was completely abolished, resulting in a score of 0. This dramatic effect was not species-specific, as introduction of the same T193_T194lnstT into human, mouse, elk, mule deer, and sheep PrP sequences similarly reduced their misfolding scores to 0, indicating a universal inhibitory effect of this single amino acid addition.

[0357] To further confirm the critical role of the threonine insertion, we generated a variant of dolphin (Tursiops truncatus) PrP with the threonine deleted at that position, thereby creating a cetacean PrP sequence with standard sequence length at this position. Remarkably, this modified dolphin PrP regained the ability to misfold spontaneously in PMSA, achieving a score of 87.1. This substantial recovery of misfolding propensityprovides compelling evidence that the threonine at this position is both necessary and sufficient to explain the prion misfolding resistance observed across cetaceans.

[0358] Extra threonine insertion prevents templated prion propagation in vitro After establishing that the insertion of a single threonine at that position prevents spontaneous misfolding of prion proteins, we next investigated whether these modified proteins could still support templated propagation of pre-existing prions. This question is particularly relevant because seed-induced propagation can often overcome barriers that prevent spontaneous misfolding, as it provides a template that can facilitate the conformational conversion process.

[0359] To address this, we conducted seeded PMSA experiments using recombinant PrP substrates with and without the extra threonine insertion. Critically, we used a homologous experimental design, where both seeds (established prion strains) and substrates (recombinant PrP) were derived from the same species to eliminate potential species barrier effects. The panel of species and prion strains tested included: bank vole with strains Ust02 and Ust09 (Eraha H, et al. Acta Neuropathol Commun.

[0360] 2023; 11(1): 145); mouse with strains btML90 and stMLOl (Perez-Castro MA, et al. PLOS Pathog. 2025;21(1):e1012890); mule deer with chronic wasting disease strains De-174C and De-174D (Diaz-Dominguez CM, et al. Neurobiol Dis. 2025;213:107005); elk with chronic wasting disease strains EI-399B and EI-399C (Diaz-Dominguez CM, et al. Neurobiol Dis. 2025;213: 107005); sheep (VRQ genotype) with strain ShVRQ9 and sheep (ARQ genotype) with strain ShARQI ; and human with strains EGM-1-3 and EGM-0-2.

[0361] For each species-strain combination, we performed seeded PMSA reactions using serial dilutions of the prion seeds ranging from 10'3to 10’8, seeding substrates containing either wild-type recombinant PrP or recombinant PrP with the threonine insertion [PrP(+T)]. PMSA reactions were conducted for 24 hours and analysed for the presence of protease-resistant PrP by proteinase K digestion, electrophoresis, and total protein staining (Figure 10).

[0362] In all cases, the wild-type recombinant proteins efficiently propagated their respective prion seeds, demonstrating robust amplification even at high seed dilutions (10-6to 10'8) in a single PMSA round, as evidenced by the accumulation of rec-PrPres(light grey boxes in heat map). In striking contrast, none of the threonine additioncontaining variants [PrP(+T)] supported detectable prion propagation at any seed dilution tested, including the highest concentration (10-3) (dark grey boxes in heat map). This complete absence of templated conversion was observed across all six species and alltwelve distinct prion strains tested, demonstrating that the protective effect of the threonine insertion could be universal and independent of both host species and prion strain conformation.

[0363] These results establish that the threonine insertion represents a remarkably potent barrier to prion propagation, effectively blocking not only spontaneous misfolding but also template-directed conversion even under highly favourable conditions with concentrated homologous prion seeds.

[0364] Multiple threonine insertions maintain resistance to prion misfolding without disrupting global protein structure

[0365] Having established that a single extra threonine is sufficient to prevent both spontaneous misfolding and templated propagation of prion proteins, we next investigated whether this effect was dependent on the specific number of additional threonines. To systematically address this question, we designed a series of bank vole PrP variants with increasing numbers of additional threonine residues at position 193 (numbered according to bank vole PrP).

[0366] We generated nine bank vole PrP variants containing 1, 2, 3, 4, 8, 12, 16, 20, and 26 additional threonine residues, respectively. Additionally, to determine whether this effect was species-specific, we generated mouse PrP variants with one and two threonine insertions at the equivalent position. All constructs were successfully expressed, purified, and subjected to our standard PMSA protocol to evaluate their spontaneous misfolding propensity. Remarkably, all variants — both from bank vole and mouse — regardless of the number of additional threonines, maintained complete resistance to spontaneous misfolding, yielding a score of 0 in our standardized assay (Figure 3).

[0367] To determine whether these extensive insertions might disrupt the overall protein structure, potentially explaining the observed resistance through a non-specific mechanism, we generated structural predictions for all variants using AlphaFold3. The predicted structures revealed that even the most extreme additional variants maintained the characteristic globular domain of PrP, with the extra threonine residues accommodated within a flexible loop region without disrupting the core structural elements — the three a-helices and two p-strands that define the native fold. The per-residue confidence scores (pLDDT) remained high across the structured domain for all variants, indicating that AlphaFold3 predicts these proteins to fold stably despite the insertions. This structural tolerance suggests that the resistance to prion misfolding conferred by an extra threonine after position 193 is robust regardless of the number ofadditional residues, and that the protective mechanism operates through specific structural constraints on the misfolding pathway rather than through global destabilization of the native protein fold.

[0368] While these AlphaFold3 predictions strongly suggested that threonine insertions are structurally tolerated without disrupting the native fold, we sought experimental validation using nuclear magnetic resonance (NMR) spectroscopy to definitively confirm that the protective mechanism operates through specific interference with pathological conversion rather than global destabilization (see below).

[0369] Amino acid specificity of insertion-mediated prion misfolding resistance To further characterize the misfolding resistance conferred by the threonine insertion at position 193, we systematically investigated whether this phenomenon was threonine-specific or could be achieved through insertion of other amino acids. We generated a comprehensive panel of bank vole PrP variants, each containing a single insertion of one of the 19 standard amino acids (excluding cysteine, which was omitted due to its propensity to form disulfide bridges that compromise proper folding and expression yield). Each variant was expressed, purified, and subjected to our standard PMSA protocol to determine its misfolding propensity score. The results revealed striking differences in the ability of different amino acids to confer resistance to misfolding (Figure 3). While threonine insertion completely abolished misfolding (score 0), insertion of several other amino acids exhibited similar protective effects, including serine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, tryptophan, histidine, lysine, and arginine (all with score 0). In contrast, other amino acid insertions had minimal impact on misfolding propensity, particularly proline (score 100), glutamic acid (score 96), glycine (score 82), aspartic acid (score 77), glutamine (score 53), asparagine (score 39), and alanine (score 17).

[0370] T o determine whether the protective effect observed with certain amino acids could be enhanced by multiple insertions, we generated additional variants with repeated insertions of serine (SS, SSS) and valine (VV, VW). All of these variants maintained complete resistance to misfolding (score 0), suggesting that the protective effect is not dependent on the number of inserted residues for these amino acids, similar to our observations with multiple threonine insertions (Figure 3).

[0371] Conversely, for alanine, which showed minimal protective effect as a single insertion (score 17), we tested whether increasing the number of inserted residues (AA, AAAA - SEQ ID NO: 151, AAAAAAAA - SEQ ID NO: 152) might enhance protection. None of these multiple alanine insertion variants showed improved resistance, allmaintaining substantial misfolding propensity. Furthermore, hybrid insertions combining alanine with a terminal threonine (AT, AAAAT - SEQ ID NO: 153) failed to rescue the protective effect, indicating that the presence of threonine cannot overcome the permissive effect of adjacent alanine residues (Figure 3).

[0372] Context dependency of the protective insertion effect

[0373] To determine whether the protective effect of amino acid insertions depends on the surrounding sequence context, particularly the conserved tetrathreonine motif (TTTT - SEQ ID NO: 1) preceding the insertion site, we designed a series of variants with modified TTTT sequences while maintaining the protective insertion.

[0374] We systematically altered the tetrathreonine motif through various substitution patterns while maintaining the additional inserted residue. Our modifications encompassed several strategic approaches to interrogate different aspects of the sequence-structure relationship. We first examined modifications to the first half of the tetrathreonine motif (AATT+T - SEQ ID NO: 3, VVTT+T - SEQ ID NO: 155, SSTT+T -SEQ ID NO: 156), followed by alterations to the second half (TAAT+T - SEQ ID NO: 157, TSST+T - SEQ ID NO: 158, TAAA+T - SEQ ID NO: 159, TSSS+T - SEQ ID NO: 160). We also created extended modifications with additional protective residues (TAAT+TT - SEQ ID NO: 161, TAAA+TT - SEQ ID NO: 5, TAAT+TTT - SEQ ID NO: 163, TAAA+TTT - SEQ ID NO: 6, SSTT+S - SEQ ID NO: 165, TTSS+T - SEQ ID NO: 166, SSSS+S - SEQ ID NO: 167) and variants with single threonine replacements at each position throughout the motif (TTTA+T - SEQ ID NO: 168, TTAT+T - SEQ ID NO: 169, TATT+T-SEQ ID NO: 7, ATTT+T-SEQ ID NO: 171, TTTS+T-SEQ ID NO: 172, TTST+T - SEQ ID NO: 173, TSTT+T - SEQ ID NO: 174, STTT+T - SEQ ID NO: 175). Finally, we tested alternative insertions with modified tetrathreonine motifs (TATT+A -SEQ ID NO: 176, TSTT+S - SEQ ID NO: 177) to assess the interplay between specific substitutions and insertions.

[0375] The results revealed striking context-dependency of the insertion-mediated protective effect (Figure 3). While many tetrathreonine motif modifications abolished the protective capacity of the inserted threonine — resulting in substantial misfolding propensity — a significant subset of variants maintained complete resistance to misfolding (score 0). These protective variants included: VVTTT - SEQ ID NO: 155, SSTTT - SEQ ID NO: 156, TSTTT - SEQ ID NO: 174, STTTT - SEQ ID NO: 175, and numerous modifications of the extended pentathronine Based on these findings suggesting the importance of the second position in the tetrathreonine motif, we performed systematic substitutions at the second position of the tetrathreonine motif (while maintaining theinserted threonine), revealing that 15 of 19 standard amino acids preserved complete protection (score 0): threonine, serine, valine, isoleucine, leucine, methionine, arginine, lysine, histidine, phenylalanine, tyrosine, and tryptophan. In contrast, substitutions with alanine, glycine, asparagine, glutamine, aspartate, glutamate, cysteine, or proline resulted in loss of protection, with scores ranging from 1-34 (Figure 3).

[0376] To further test the importance of the insertion versus substitution at this position, we generated a K195T variant, which effectively places a threonine immediately after the tetrathreonine motif but through substitution rather than addition. This variant maintained substantial misfolding propensity, confirming that the protective effect requires an additional residue rather than merely the presence of threonine at this position. Similarly, extending the natural tetrathreonine motif by substituting the preceding valine with threonine (V190T, creating a pentathronine sequence TTTTT - SEQ ID NO: 2) did not confer protection, while adding an extra to this extended threonine sequence did prevent misfolding (Table 4, SEQ ID NO: 198 and 199). These results further support the conclusion that it is specifically the insertion that disrupts the misfolding process, rather than simply the amino acid composition or length of the threonine-rich region.

[0377] Based on these findings suggesting the importance of the second position in the tetrathreonine motif, we conducted a comprehensive scan by generating variants with all 19 standard amino acids (excluding cysteine) at this position while maintaining the protective threonine insertion. The results revealed that most substitutions at this position preserved the protective effect of the insertion, with only three exceptions: glycine, asparagine, and glutamine (the latter showing a minimal score of 1) allowed substantial misfolding despite the presence of the protective insertion (Figure 3).

[0378] Table 4. Deletion mutagenesis of the poly-threonine region reveals differential requirements for spontaneous misfolding

[0379] 5' sequence Modified 3' sequence Score SE sequence Q ID NO:

[0380] NNQNNFVHDCVNITKQHTV TTT KGENFTETDVKMMER 100 182

[0381] NNQNNFVHDCVNITKQHTV TT KGENFTETDVKMMER 100 183

[0382] NNQNNFVHDCVNITKQHTV T KGENFTETDVKMMER 100 184

[0383]

[0384] 5' sequence Modified 3' sequence Score SE sequence Q ID NO:

[0385] NNQNNFVHDCVNITKQHTV — KGENFTETDVKMMER 100 185

[0386] NNQNNFVHDCVNITKQHTV — GENFTETDVKMMER 100 186 NNQNNFVHDCVNITKQHTV — ENFTETDVKMMER 86 187 NNQNNFVHDCVNITKQHTV — NFTETDVKMMER 0 188 NNQNNFVHDCVNITKQHTV — FTETDVKMMER 1 189 NNQNNFVHDCVNITKQH — KGENFTETDVKMMER 86 190

[0387] NNQNNFVHDCVNITKQH — GENFTETDVKMMER 56 191 NNQNNFVHDCVNITKQH — ENFTETDVKMMER 5 192 NNQNNFVHDCVNITKQH — FTETDVKMMER 5 193 NNQNNFVHDCVNITK — FTETDVKMMER 0 194 NNQNNFVHDCVNITK — DVKMMER 0 195 NNQNNFVHDCVNITKQHTV — DVKMMER 0 196 NNQNNFVHDCVNITK — KGENFTETDVKMMER 0 197

[0388] NNQNNFVHDCVTNITKQHT I l l i KGENFTETDVKMMER 98 202 T NNQNNFVHDCVTNITKQHT 1 1 1 1 1 KGENFTETDVKMMER 0 203 T NNQNNFVHDCVNITKQHTV I l l i TGENFTETDVKMMER 14 204

[0389]

[0390] Systematic deletion analysis of the poly-threonine region reveals important residues for prion misfolding

[0391] Given the significant impact of insertions in the poly-threonine region on misfolding propensity, we next investigated the effect of deletions within this region. This complementary approach aimed to determine whether the tetrathreonine motif itself is essential for prion misfolding or if other neighboring residues play critical roles in the conformational conversion process.

[0392] We systematically generated a series of deletion variants, progressively removing threonine residues from the conserved tetrathreonine motif (TTTT - SEQ ID NO: 1).Surprisingly, the sequential deletion of one, two, three, or even all four threonine residues had minimal impact on misfolding propensity, with all variants maintaining misfolding scores comparable to wild-type bank vole PrP (Table 4). This finding contrasts sharply with our insertion experiments and indicates that while insertions in this region can prevent misfolding, the threonine residues themselves are not essential for the misfolding process.

[0393] To extend this analysis, we generated variants with deletions in the regions flanking the tetrathreonine motif (Table 4). Deletion of the lysine and glycine residues immediately following the tetrathreonine motif [ATTTTKG - SEQ ID NO: 198 (p.Thr191_Gly196del; c.571_5888del)] similarly had minimal effect on misfolding propensity. However, when the deletion was extended to include the subsequent glutamictic acid residue [ATTTTKGE - SEQ ID NO: 199 (p.Thr191_Asn198del; c.571_594del)], misfolding was completely abolished (score 0). This finding identifies the asparagine residue as an important element for prion protein misfolding, despite being located several positions away from the insertion site that confers resistance in cetacean PrP.

[0394] We also examined deletions at the N-terminal side of the tetrathreonine motif. Removal of the threonine and valine residues preceding the tetrathreonine sequence [ATVTTTT-SEQ ID NO: 200 (p.Thr189_Thr194del; c.565_582del)] had minimal impact on misfolding propensity. However, combined deletions from both flanking regions produced a more substantial effect, as demonstrated by the [ATVTTTTKG - SEQ ID NO: 201 (p.Thr191_Gly198del; c.565_588del)] deletion variant, which showed a dramatically reduced misfolding score of 5.

[0395] Single threonine insertion provides strain-dependent protection against prion disease

[0396] To validate our in vitro findings in a living system, we developed a novel transgenic mouse model using CRISPR-Cas9 gene editing technology. Building upon our previously established TgMo(L108l)1x mouse model (Eraha H et al. Brain Pathol..

[0397] 2026;e70083) — which expresses mouse PrP with the L108I substitution that accelerates prion disease progression without altering strain properties — we generated a new transgenic line incorporating a single extra threonine at position 192: TgMo(L108l lns192T)1x.

[0398] Groups of 5-7 animals (6-7 weeks old) were inoculated with three well-characterized mouse-adapted scrapie strains — RML, 22L, and ME7 — using both intracerebral and intraperitoneal routes of infection. The results revealed a striking straindependent protection conferred by the threonine insertion (Table 5).For RML prions, TgMo(L108l lns192T)1x mice showed significant extension of incubation periods: a 32% increase following intracerebral inoculation (from 113±2 to 166±1 days post-inoculation, dpi) and a 36% increase following intraperitoneal inoculation (from 147±2 to 200±5 dpi). The protective effect was substantially more pronounced against 22L prions, with the single additional threonine extending incubation periods by 103% following intracerebral inoculation (from 167±2 to 338±22 dpi) and 109% following intraperitoneal inoculation (from 197±13 to 412±61 dpi). The greatest sensitivity to the single threonine insertion was observed for ME7 prions, which showed the largest relative extension among completed experiments: 153% following intracerebral inoculation (from 160±1 to 405±4 dpi). Intraperitoneal inoculation with ME7 also yielded a substantial delay (>125% extension, from 212±6 to >470 dpi), with the experiment still ongoing at the time of writing.

[0399] Table 5. Strain-dependent protective effects of single threonine insertion on prion disease progression.

[0400] Incubation prpres Inoculation Attack period %a(WB) Inoculum Animal model

[0401] route rate (dpi ±

[0402] SEM)

[0403] TgMo(L1081)1 x ic 6 / 6 113 ± 2 NA 6 / 6 TgMo(L108l)1x ip 7 / 7 147 ± 2 NA 7 / 7 TgMo(L108l

[0404] RML ic 5 / 5 166 ± 1 32 5 / 5 lns192T)1x

[0405] TgMo(L108l

[0406] ip 7 / 7 200 ± 5 36 7 / 7 lns192T)1x

[0407] TgMo(L1081)1 x ic 5 / 5 164 ± 2 NA 5 / 5 TgMo(L1081)1 x ip 5 / 5 197 ± 13 NA 5 / 5 TgMo(L108l

[0408] 22L ic 6 / 6 338 ± 22 103 6 / 6 lns192T)1x

[0409] TgMo(L108l

[0410] ip 5 / 6 412 ± 61b109 5 / 6 lns192T)1x

[0411] TgMo(L1081)1 x ic 7 / 7 160 ± 1 NA 7 / 7MF7TgMo(L1081)1 x ip 6 / 6 212 ± 6 NA 6 / 6 TgMo(L108l

[0412] ic 5 / 5 405 ± 4 153 5 / 5 lns192T)1xTgMo(L108l

[0413] ip 5 / 6c>470 >125% 0 / 5 lns192T)1x

[0414] aPercentage values indicate the extension of incubation period (in %) relative to the baseline incubation period observed in TgMo(L1081)1 x control mice inoculated with the same prion strain and route.

[0415] bTwo animals were euthanized at 600 days post-inoculation for scheduled endpoint analysis, of which only one showed biochemical evidence of protease-resistant PrP (Prpres) by Western blot.

[0416] cOne animal was euthanized at 329 days post-inoculation due to severe refractory dermatitis unresponsive to treatment. This animal showed no biochemical evidence of PrPresand was excluded from attack rate and incubation period calculations.

[0417] Biochemical analysis of brain tissues revealed the characteristic three-band pattern of protease-resistant PrP (PrPres) for both RML, 22L, and ME7 strains, with glycoform ratios and electrophoretic mobility identical to those observed in control TgMo(L108l)1x mice (Figure 11A).

[0418] Histopathological and immunohistochemical analysis of brain tissues revealed strain-specific lesion and PrPresdeposition patterns characteristic of RML, 22L and ME7 strains (Figure 11B). While the overall distribution patterns remained consistent with those observed in control TgMo(L108l)1x mice, notable differences in lesion intensity were detected. For intracerebrally RML-infected TgMo(L108l lns192T)1x mice, spongiform lesions showed reduced intensity in several brain regions including the neocortex, mesencephalon, medulla oblongata, and cerebellar cortex compared to TgMo(L108l)1x controls, while maintaining the cortical involvement typical of this strain. Conversely, the immunolabelling of PrPresdeposits was more intense in TgMo(L108l lns192T)1x mice, particularly in the forebrain. The longer incubation period of these animals might explain the higher immunolabelling intensity even though the lesion associated to it was, counterintuitively, milder. Intraperitoneal inoculation of RML resulted in similar lesion profiles, with TgMo(L108l lns192T)1x mice showing milder spongiosis in brainstem than in TgMo(L108l)1x, but with more severe lesions in hippocampus and occipital cortex, in agreement in this case with the considerably higher PrPresimmunolabeling than in the control group, most likely linked to their even longer incubation period. In the case of 22L-infected TgMo(L108l lns192T)1x mice also exhibited the characteristic 22L cerebellar pathology but, again, with clearly diminished lesion intensity in regions such as the neocortex, hippocampus, and piriform cortex.Regarding PrPresdeposits, a relatively more intense staining in the hypothalamus and mesencephalon was observed when compared to TgMo(L108l)1x mice alongside with lower intensity in the neocortex, in accordance, in this occasion, with the milder spongiosis intensity. In this case, despite technical problems with brain sampling from the intraperitoneally inoculated mice difficulted accurate comparisons, a similar trend could be found with milder spongiform lesions and more intense PrPresdeposits in the most affected cerebellar region. Histopathological and immunohistochemical analysis of intracerebrally ME7-infected TgMo(L108l lns192T)1x mice showed similar spongiosis profile to TgMo(L108l)1x mice but with higher scores in the hypothalamus and mesencephalon. Similarly higher immunostaining score were observed in these two regions in the TgMo(L108l lns192T)1x group but, conversely, with lower PrPresscores in the medulla oblongata and cerebellar structures.. The preservation of strain-specific deposition patterns with altered intensity profiles suggests that the threonine insertion modulates the propagation efficiency of prion strains without fundamentally altering their neuroanatomical targeting preferences, consistent with a mechanism that impairs, but does not completely prevent, the templated conversion process.

[0419] Enhanced protection with double threonine insertion demonstrates dosedependent effect and reveals prion strain adaptation

[0420] While our in vitro studies revealed that multiple threonine insertions all completely prevented misfolding (all scoring 0), these assays could not distinguish potential differences in protective strength beyond complete inhibition. We therefore questioned whether additional threonine insertions might enhance the protective effect in vivo, where the complex cellular environment and prolonged incubation periods could reveal more subtle variations in protective capacity.

[0421] To address this question, we generated a second transgenic mouse line — TgMo(L108l lns192TT)1x — incorporating two extra threonines at position 192. Groups of 6 animals were challenged with RML, 22L, and ME7 prion strains using identical routes of inoculation as in our previous experiment.

[0422] The results were remarkable. TgMo(L108l lns192TT)1x mice exhibited extraordinary resistance to all three prion strains tested (Table 6). For RML prions, disease onset was delayed by more than 350% following intracerebral inoculation (from 113±2 to >530 dpi, with observation ongoing) and 237% following intraperitoneal inoculation (from 147±2 to 496±24 days post-inoculation). For 22L prions, no clinical signs of disease have been observed after more than 530 days post-inoculation for both intracerebral (>225% extension from 167±2 baseline, observation ongoing) andintraperitoneal routes (>170% extension from 197±13 baseline, observation ongoing). Similarly, ME7-inoculated TgMo(L108l lns192TT)1x mice have remained asymptomatic beyond 530 days post-inoculation for both routes (>180% extension from 160±1 baseline for IC; >125% extension from 212±6 baseline for IP, observation ongoing for both).

[0423] Biochemical and immunohistochemical analyses could only be performed on the subset of RML-infected TgMo(L108l lns192TT)1x mice that eventually developed clinical signs following intraperitoneal inoculation, as animals inoculated with 22L and ME7 strains remain alive and under observation (>530 dpi) with no sign of neurological impairment. Western blot analysis of brain tissues from terminally ill RML-infected mice revealed a significant transformation of the PrPresbiochemical profile (Figure 12A): a marked shift in the glycoform ratio, with the diglycosylated band becoming more prominent compared to the monoglycosylated band that typically predominates in wildtype RML, accompanied by an apparent change in the electrophoretic mobility of the unglycosylated band. These alterations suggest that prolonged propagation under the selective pressure imposed by the double threonine insertion barrier selected for a structurally adapted RML conformer. However, the neuropathological assessment of the intraperitoneally RML-infected TgMo(L108l lns192TT)1x mice revealed an RML-characteristic synaptic PrPresimmunostaining pattern, with involvement of the neocortex albeit with lower lesion and immunostaining intensity in the neocortex, hippocampus, pyriform cortex and brain stem when compared to TgMo(L108l)1x mice. Despite this group of animals displayed high inter-individual variability, with two animals showing milder phenotypes with more prominent involvement of the brainstem and lesser involvement of the neocortex, the neuropathological findings point towards the conservation of the pathobiological features of the strain in the new genotype regardless of the biochemical differences observed (Figure 12B). Critically, when RML(+TT) was subsequently passaged into wild-type C57BL / 6 mice, the PrPresprofile reverted to a pattern indistinguishable from that of the parental RML strain (Figure 13A), demonstrating that these biochemical changes represent transient conformational accommodations to the double-insertion environment rather than permanent strain transformation. This biochemical adaptation was accompanied by corresponding alterations in the immunohistochemical distribution pattern of PrPresdeposits throughout the brain, suggesting that prolonged propagation in the presence of the double threonine insertion barrier selected for a structurally adapted RML conformer capable of overcoming this constraint.These findings demonstrate a clear dose-dependent protective effect: while a single threonine insertion provides partial, strain-dependent protection (32-153% extension depending on strain and route), double insertion confers dramatically enhanced resistance (237% to >350% extension, with multiple groups still under observation). Notably, within the observation periods completed to date, RML prions have shown the capacity to adapt and eventually cause disease despite the doubleinsertion barrier, whereas 22L and ME7 prions have not yet caused clinical disease. Whether the sustained resistance to 22L and ME7 represents absolute blockade or merely more stringent kinetic barriers that would eventually be overcome with longer observation periods remains to be determined.

[0424] Table 6. Double-threonine insertion provides enhanced, strain-dependent protection against prion disease in transgenic mouse models

[0425] Incubatio

[0426] Inoculum Inoculatio Attac n period PrPres (WB)

[0427] Animal model %a

[0428] n route k rate (dpi +

[0429] SEM)

[0430] TgMo(L108l lns192TT)1x >350

[0431] RML ic 5 / 5 361 ±53 1 / 5

[0432] TgMo(L108l lns192TT)1x

[0433] RML ip 6 / 6 496 ±24 237 6 / 6

[0434] TgMo(L108l lns192TT)1x >225

[0435] 22L ic 6 / 6 >530 0 / 6

[0436] TgMo(L108l lns192TT)1x >225

[0437] 22L ip 6 / 6 >530 0 / 6

[0438] TgMo(L108l lns192TT)1x >180

[0439] ME7 ic 6 / 6 >450 0 / 6

[0440] TgMo(L108l lns192TT)1x >125

[0441] ME7 ip 6 / 6 >450 0 / 6

[0442]

[0443] aPercentage values indicate the extension of incubation period (in %) relative to the baseline incubation period observed in TgMo(L108l)1x control mice inoculated with the same prion strain and route (see Table 5 for baseline values).

[0444] bOne animal was euthanized at 610 days post inoculation for scheduled endpoint analysis. Although this animal showed no overt clinical signs of prion disease, Western blot analysis revealed biochemical evidence of protease-resistant PrP (PrPres) accumulation in brain tissue, indicating subclinical infection.cOne animal was euthanized at 443 days post inoculation due to an intercurrent illness unrelated to prion disease. This animal showed no biochemical evidence of PrPres and was excluded from attack-rate and incubation-period calculations.

[0445] Second passage experiments reveal strain stability and non-sequential adaptation to threonine insertions

[0446] To further characterize the relationship between prion strain properties and threonine insertion-mediated protection, we conducted comprehensive second passage experiments. We serially passaged prions that had propagated in TgMo(L108l lns192T)1x mice — referred to as RML(+T) and 22L(+T) — into three different host models: wild-type C57BL / 6 mice, TgMo(L108l lns192T)1x mice (homologous passage), and TgMo(L108l lns192TT)1x mice (increased barrier).

[0447] When RML(+T) and 22L(+T) were inoculated into wild-type C57BL / 6 mice, which express PrP without any additional threonines, the incubation periods were remarkably similar to those of the original RML and 22L strains in C57BL / 6 controls and electrophoretic mobility profiles were also maintained (Table 7 and figure 13A). Similarly, lesion distribution profiles for RML(+T) and 22L(+T) in the brains of inoculated wild type mice were similar to those of their original counterparts but with a decrease in the intensity of the PrPresimmunohistochemical scores in both strains. Remarkably, the immunostaining synaptic-like pattern was also maintained in the (+T) strains (Figure 13B). This finding demonstrates that propagation in the presence of a single threonine insertion does not induce permanent conformational changes that persist upon return to a wild-type PrP environment. These second passage results corroborate our immunohistochemical observations (Figure 11), which showed that prions propagating in TgMo(L108l lns192T)1x mice, maintained strain-specific neuroanatomical targeting patterns characteristic of the parental strains, albeit with altered deposition intensity. Taken together, these data indicate that the single threonine insertion creates a kinetic barrier that delays prion propagation without fundamentally altering strain conformation.

[0448] When RML(+T) and 22L(+T) were passaged back into TgMo(L108l lns192T)1x mice, both strains propagated efficiently with 100% attack rates and incubation periods comparable to each other (Table 7). This efficient propagation confirms that these prions had indeed adapted to the structural constraint imposed by the single threonine insertion during their initial passage, enabling them to overcome this barrier in subsequent transmissions. The similar propagation kinetics of RML(+T) and 22L(+T) in TgMo(L108l lns192T)1x mice, despite their markedly different behaviors during primary passage,suggests that once adapted, both strains achieve comparable efficiency in converting PrPccontaining a single threonine insertion.

[0449] Table 7. Serial passage experiments demonstrate strain stability and nonsequential adaptation of prions to threonine insertion barriers.

[0450] Incubation prpresAnimal Inoculation Attack

[0451] Inoculum period (WB) model route rate

[0452] (dpi ± SEM) C57BL / 6 ic 6 / 6 167 ± 3 6 / 6 TgMo(L108l

[0453] ic 6 / 6 162 ± 1 6 / 6 RML(+T) lns192T)1x

[0454] TgMo(L108l

[0455] ic 6 / 6 >450 0 / 6 lns192TT)1x

[0456] C57BL / 6 ic 5 / 5 222 ± 3 5 / 5 TgMo(L108l

[0457] 22L ic 3 / 3 186 ± 0 3 / 3

[0458] lns192T)1x

[0459] TgMo(L108l

[0460] ic 5 / 5 >450 0 / 5 lns192TT)1x

[0461] RML(+TT) C57BL / 6 ic 6 / 6 193 ± 5 6 / 6

[0462] To determine whether adaptation to a single extra threonine might enable prions to more readily overcome the more stringent barrier imposed by double threonine insertion, we inoculated RML(+T) and 22L(+T) into TgMo(L108l lns192TT)1x mice. Strikingly, both adapted strains remained unable to cause disease within extended observation periods (Table 7), exhibiting resistance comparable to that observed with the original RML and 22L strains in this model (Table 6). This finding indicates that the adaptive process is not sequential — that is, prions that have adapted to propagate in the presence of one threonine insertion do not thereby acquire an enhanced capacity to overcome the constraint imposed by two additional threonines.

[0463] Our analysis of RML prions that eventually propagated in TgMo(L108l lns192TT)1x mice — designated RML(+TT) — revealed significant biochemical alterations, including shifts in glycoform ratios (Figure 12), suggesting potential strain transformation. To test whether these biochemical changes represented stable, heritable alterations to the prion conformation, we passaged RML(+TT) back into wild-type C57BL / 6 mice. Remarkably, the incubation periods and attack rates in C57BL / 6 mice inoculated with RML(+TT) were indistinguishable from those obtained with the original RML strain (Table 7 and Figure13). This reversion to parental properties upon removal of the selection pressure demonstrates that the biochemical alterations observed in RML(+TT) represent transient conformational accommodations to the double-addition environment rather than permanent strain transformation.

[0464] Threonine additions preserve the native structure of prion protein while preventing pathological conversion

[0465] Following our in vivo observations that threonine insertions in PrP confer strong resistance to prion propagation, we next determined whether these modifications perturb the three-dimensional structure of the native protein. Among the engineered variants, the double threonine insertion (lns192TT) exhibited the most dramatic protective effect against prion propagation, with near-complete resistance to multiple prion strains and extended observation periods exceeding 450 days. We therefore focused our structural analysis on this variant to determine whether such profound functional effects could be attributed to global structural disruption rather than specific interference with the pathological conversion process.

[0466] To address this, we employed solution NMR spectroscopy to characterize recombinant human PrP carrying the lns192TT insertion. Human PrP was selected for this analysis because: (1) the poly-threonine region and insertion site are identical between human and mouse PrP, with >95% sequence identity in the structured C-terminal domain; (2) human PrP benefits from extensive available data, including complete chemical shift assignments (BMRB 4402) and high-resolution NMR structures (PDB 1QLZ) (Castilla J, et al. Arch Virol. 2003;148(4):677-691); and (3) findings with human PrP have direct translational relevance. Given the high conservation of this region across mammals, structural conclusions are generalizable to the mouse orthologs used in our in vivo studies.

[0467] The resulting NMR ensemble (10 conformers, PDB 9TVY) defines a well-converged core spanning residues 121-166 and 171-233, with a backbone RMSD of 0.53 A over the ordered regions (Figure 14A). Comparison of the lns192TT structure with the wild-type PrP reference revealed preservation of the overall fold of the globular C-terminal domain (Fig. 14A). Structural overlay with PDB entry 1QLZ showed close agreement in the spatial arrangement of the three a-helices (a1-a3) and the antiparallel P-sheet, with no evidence of large-scale rearrangements. A local structural view centered on the insertion site demonstrated that the additional threonine residues are accommodated without introducing steric clashes or disrupting the surrounding secondary structure elements (Fig. 14B).To assess more subtle structural effects, we compared backbone amide chemical shifts of lns192TT PrP (BMRB 35030) with those of wild-type PrP from BMRB 4402. The resulting chemical shift perturbations (CSPs) were small for the majority of residues and remained below typical thresholds for significant structural reorganization (Fig. 14C). Perturbations were predominantly localized near the insertion site and in spatially proximal regions, indicating that the modification induces only limited, local changes in the chemical environment. Mapping CSP values onto the three-dimensional structure further confirmed that these effects cluster near the insertion region and do not extend across the folded domain (Fig. 14C inset).

[0468] Together, these data demonstrate that insertion of two threonine residues in the tetrathreonine motif does not compromise the native fold or stability of PrP. Instead, the mutation induces only localized structural perturbations near the insertion site while preserving the global architecture of the protein. This structural preservation is consistent with our biochemical observations that the lns192TT variant can be expressed, purified, and refolded similarly to wild-type PrP. Importantly, these findings support a model in which threonine insertion confers resistance to prion propagation not by destabilizing the native state, but by selectively interfering with conformational conversion into the pathogenic PrPScform. This combination of structural integrity and functional resistance suggests that minimally modified PrP variants may act as dominant-negative inhibitors of prion conversion and highlights the therapeutic potential of targeting specific structural elements involved in misfolding.

[0469] Computational modeling reveals structural basis for strain-dependent effects of threonine insertions

[0470] Our observations of differential protective effects against distinct prion strains, particularly the greater resistance conferred by threonine insertions against 22L compared to RML, prompted us to investigate the molecular mechanisms underlying this strain-dependent phenomenon. While comprehensive structural characterization of modified prion fibrils would require extensive experimental efforts, we employed available cryo-EM structures of 22L (PDB ID: 8EFLI) and RML (PDB ID: 7QIG) fibrils, together with computational techniques, to model how the threonine insertion may distort the local fibril geometry and impair the alignment between wild-type and lns192T chains during fibril elongation. To this end, we performed molecular dynamics (MD) simulations on murine wild-type fibrils, lns192T fibrils, and mixed fibrils containing both wild-type and lns192T monomers with a wild-type- lns192T interface for both strains, yielding six distinct models in total. Analysis of the mixed wild-type / lns192T fibrils allows us toevaluate the impact of the sequence mismatch between monomers (presence or absence of the additional threonine) on the structure and dynamics of each strain in comparison with the corresponding isolated pure fibrils. Root-mean-square fluctuation (RMSF) values obtained from the MD simulations provide residue-level insights into local flexibility for the C-terminal lobe of all six models. RMSF data for the complete fibril structures are presented in Figure 15.

[0471] RMSF values reveal that the tip of the C-terminal lobe — where the tetrathreonine motif is located in both fibril types — is the most flexible region of the amyloid core, consistent with cryo-EM local resolution data (Manka SW, et al. Nat Commun.

[0472] 2022;13(1):4004). Comparison between wild-type and lns192T fibrils indicates that the threonine insertion modulates local fibril flexibility in a strain-dependent manner: it reduces flexibility at the C-terminal lobe tip in 22L, while increasing it in RML (Figure 15). Distributions of inter-rung distances along the molecular dynamics trajectories (Figure 16) show that the threonine insertion does not markedly destabilize the overall fibril architecture (lns192T fibril). This observation aligns with our in vivo results, where RML prions carrying a single threonine insertion exhibited delayed but eventual disease progression in mice. In contrast, mixed fibrils composed of wild-type and lns192T monomers (50:50 ratio) display elevated RMSF values. For both strains, increased fluctuations are observed near the insertion site, reflecting the local sequence mismatch at the WT / lns192T interface. This mismatch also results in looser p-sheet packing, with a shift toward higher inter-rung distances (Figure 16). Notably, the 22L mixed WT / lns192T model exhibits greater RMSF deviations from its corresponding pure fibrils (WT and lns192T) than does the RML mixed WT / lns192T model, indicating a larger structural mismatch in the former that matches the longer incubation periods observed for 22L relative to RML.

[0473] Our computational findings reveal that the threonine insertion modulates local fibril flexibility in a strain-dependent manner. Analysis of root-mean-square fluctuation (RMSF) values shows that the insertion reduces flexibility at the C-terminal lobe tip in 22L fibrils while increasing it in RML fibrils. Moreover, mixed fibrils containing both wildtype and lns192T monomers exhibit elevated RMSF values near the insertion site, with the 22L mixed model showing greater structural perturbations from its corresponding pure fibrils than the RML mixed model. These differential effects on fibril dynamics correlate with the observed differences in protective efficacy in vivo, where the threonine insertion provided greater protection against 22L (103-109% extension) compared to RML (32-36% extension).While these simulations do not definitively explain the mechanistic basis for strainspecific protection, they demonstrate that threonine insertions alter the structural and dynamic properties of prion fibrils in ways that differ between strains. This combined experimental and computational approach highlights the complex interplay between prion protein sequence and strain-specific conformational constraints, providing a foundation for future studies aimed at understanding the molecular determinants of prion transmission barriers.

Claims

83CLAIMS1. A mutant prion protein wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO:2) motif of the wild-type sequence is replaced by the sequence:(S / V / T)(Z)mTT(X)nwhereinZ is an amino acid selected from the group consisting of A, P, E, G, D, H, I, F, K, L, M, Q, R, S, T, V, Wand Y,m is an integer number between 1 and 3,X is an amino acid selected from the group consisting of A, F, H, I, K, L, M, R, S, T, V, Wand Y,n is an integer number between 1 and 30,and wherein if the wild-type protein has the TTTTT motif, thenif Z is T and X is T, then n is not 1 ,if Z is T and n is 1 , then X is not Tif X is T and n is 1 , then Z is not T.

2. The mutant prion protein according to claim 1, wherein said mutant prion protein is not capable of being converted into the amyloid-like, disease-associated form of the prion protein.

3. The mutant prion protein according to claim 2, wherein said mutant prion protein has an inhibitory effect on the conversion of an endogenous wild-type prion protein that is naturally present in an organism.

4. The mutant prion protein according to any one of claims 1 to 3, wherein X is an amino acid selected from the group consisting of T, S and V.

5. The mutant prion protein according to claim 4, wherein n is a number between 1 and 15.

6. The mutant prion protein according to any one of claims 1 to 5, wherein Z is an amino acid selected from the group consisting of P, E, D, H, I, F, K, L, M, R, S, T, V, Wand Y.

7. The mutant prion protein according to any one of claims 1 to 6, wherein the TTTT (SEQ ID NO: 1) or TTTTT (SEQ ID NO: 2) motif of the wild-type protein is replaced by a sequence selected from the group consisting of:TTTT(T)n, wherein n is a number between 1 and 30,TTTTX, wherein X is selected from the group consisting of A, S, V, F, L, I, M, Y, H, Wand R,TTTT(S)n, wherein n is 2 or 3,84TTTT(V)n, wherein n is 2 or 3,- SSTTT (SEQ ID NO: 4),- TAAATT (SEQ ID NO: 5),- TAAATTT (SEQ ID NO: 6),- TATTT (SEQ ID NO: 7),TZTTT (SEQ ID NO: 8), wherein Z is selected from the group consisting of: K, R, S, V, Y, P, F, E, D, H, L, I, M, Q and W.

8. The mutant prion protein according to any one of claims 1 to 7, wherein the wild type prion protein is a naturally occurring protein.

9. The mutant prion protein according to claim 8, wherein the wild type prion protein is a naturally occurring protein with a protein sequence selected from a group consisting of: NCBI Protein database accession number NP_001073592.1, entry version 1 of February 3, 2026, NCBI Protein database accession number XTQ94710.1, entry version 1 of July 1, 2025, NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, and NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026.

10. The mutant prion protein according to claim 8, wherein the wild-type prion protein is a prion protein naturally occurring with at least 80% identity across the whole length of the protein sequence of the protein sequence with the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026.

11. The mutant prion protein according to any of claims 1 to 10, wherein the mutant prion protein is a protein that does not exist in nature and comprises less than 99.5% sequence identity with the corresponding wild type sequence which is selected from a group consisting of: NCBI Protein database accession number NP_001073592.1, entry version 1 of February 3, 2026, NCBI Protein database accession number AAH 12844.1, entry version 1 of September 23, 2014, NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025,85NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, and NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026.

12. The mutant prion protein according to any of claims 1 to 11, wherein the mutant prion protein does not exist in nature and comprises:a protein sequence according to the accession number NP_001073592.1 of the NCBI Protein database, entry version 1 of February 3, 2026, wherein the amino acids at positions 190-193, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number XTO94710.1, entry version 1 of July 1, 2025, wherein the amino acids at positions 190-193, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2 , SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number NP_035300.1, entry version 1 of April 7, 2026, wherein the amino acids at positions 189-192, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number AAR01535.1, entry version 1 of June 23, 2010, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number BBD75294.1, entry version 1 of April 14, 2020, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein86sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number NP_001301176.1, entry version 1 of April 3, 2025, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number NP_001008687.1, entry version 1 of April 2, 2025, wherein the amino acids at positions 194-197, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number AAM73856.1, entry version 1 of July 2, 2002, wherein the amino acids at positions 209-212, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143;a protein sequence according to the accession number NCBI Protein database accession number AAB70468.1, entry version 1 of September 1997, wherein the amino acids at positions 193-196, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143; ora protein sequence according to the accession number NCBI Protein database accession number NP_001265185.1, entry version 1 of April 7, 2026, wherein the amino acids at positions 189-192, inclusive, are substituted by a protein sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4-13, SEQ ID NO: 114-132, and SEQ ID NO: 134-143.

13. A nucleic acid encoding the mutant prion protein according to any one of claims 1 to 12.

14. An expression vector comprising the nucleic acid according to claim 13.

15. The expression vector according to claim 14, wherein said viral vector is an adeno-associated viral vector (AAV).

16. A host cell comprising the nucleic acid according to claim 13 or the expression vector according to claim 14 or 15.8717. A pharmaceutical composition comprising the mutant prion protein according to any one of claims 1 to 12, the nucleic acid according to claim 13, the vector according to claim 14 or 15, or the host cell according to claim 16, together with at least one pharmaceutically acceptable excipient.

18. The mutant prion protein according to any one of claims 1 to 12, the nucleic acid according to claim 13, the expression vector according to claim 14 or 15, the host cell according to claim 16 or the pharmaceutical composition according to claim 17 for use in medicine.

19. The mutant prion protein according to any one of claims 1 to 12, the nucleic acid according to claim 13, the expression vector according to claim 14 or 15, the host cell according to claim 16 or the pharmaceutical composition according to claim 17 for use in the treatment and / or prevention of a prion disease.

20. The mutant prion protein, nucleic acid, expression vector, host cell or pharmaceutical composition for use according to claim 19, wherein the prion disease is selected from the group consisting of Creutzfeldt-Jakob diseases (CJD), fatal familial insomnia (FFI), Gerstmann-Straussler-Scheinker syndrome (GSS), scrapie, bovine spongiform encephalopathy, chronic wasting disease, Variably Protease-Sensitive Prionopathy (VPSPr) and Prion Protein Systemic Amyloidosis.